hydralazine has been researched along with Cardiac Failure in 500 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 9.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "To investigate the effects of hydralazine combined with nitrate on serum levels of Adropin and brain natriuretic peptide (BNP), left ventricular remodeling and prognosis in patients with chronic heart failure (CHF)." | 9.41 | Combined effects of hydralazine and nitrate on serum biochemistry and left ventricular remodeling in chronic heart failure patients. ( Lu, Y; Qian, L; Xu, W; Yuan, X, 2021) |
| "Patients with acute heart failure (HF) in Africa are rarely being treated with a hydralazine/nitrates combination." | 9.22 | Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF). ( Ba, SA; Cotter, G; Damasceno, A; Davison, BA; Dzudie, A; Edwards, C; Kouam, CK; Mayosi, BM; Milo, O; Mondo, C; Ogah, O; Ogola, E; Ojji, D; Sani, MU; Sliwa, K; Yonga, G, 2016) |
| "Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hospitalization for heart failure (HF) by 37% in the African-American Heart Failure Trial (A-HeFT)." | 9.19 | Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial. ( Anand, IS; Cohn, JN; Rector, TS; Taylor, AL; Win, S, 2014) |
| "Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) significantly improved outcomes in patients with advanced heart failure (HF) receiving background neurohormonal therapy in the African-American Heart Failure Trial (A-HeFT)." | 9.16 | Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. ( Archambault, WT; Cohn, JN; Ghali, JK; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M; Ziesche, S, 2012) |
| "The A-HeFT trial demonstrated incremental survival with hydralazine/isosorbide dinitrate combination in African-American patients with chronic heart failure (CHF)." | 9.14 | Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure. ( Chirkov, YY; De Sciscio, M; Horowitz, JD; Leslie, S; Sage, PR; Sverdlov, AL, 2010) |
| "We previously reported that the fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC I/H) significantly decreased the risk of all-cause death and first hospitalization for heart failure (HF) and improved quality of life in patients with New York Heart Association class III or IV heart failure in the African-American Heart Failure Trial (A-HeFT)." | 9.12 | Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. ( Adams, K; Carson, P; Cohn, JN; Ferdinand, K; Ofili, E; Olukotun, AY; Sabolinski, ML; Tam, SW; Taylor, AL; Taylor, M; Worcel, M; Yancy, CW; Ziesche, S, 2007) |
| "Isosorbide dinitrate combined with hydralazine therapy compared with placebo in patients with heart failure resulted in a sustained increase in left ventricular (LV) ejection fraction (EF) indicative of regression of LV remodeling in the first Vasodilator-Heart Failure Trial (V-HeFT-I) in patients receiving only digoxin and diuretic." | 9.12 | Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. ( Anand, IS; Cohn, JN; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2007) |
| "The benefits of fixed-dose combination isosorbide dinitrate plus hydralazine (ID/H) in African-Americans with heart failure (HF) were established by the African-American Heart Failure Trial (A-HeFT), which was terminated early because of a significant survival benefit of ID/H." | 9.12 | Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). ( Archambault, WT; Braman, VM; Franciosa, JA; Ghali, JK; Sabolinski, ML; Worcel, M; Yancy, CW, 2007) |
| "In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved patient reported functional status compared with standard therapy alone." | 9.12 | Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. ( Cohn, JN; Curry, CL; Ferdinand, KC; Ghali, JK; Lindenfeld, J; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2007) |
| "We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy." | 9.11 | Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. ( Adams, K; Carson, P; Cohn, JN; D'Agostino, R; Ferdinand, K; Sabolinski, M; Taylor, AL; Taylor, M; Worcel, M; Yancy, C; Ziesche, S, 2004) |
| "This study was designed to determine the effect of oral hydralazine on the development of nitrate tolerance in patients with chronic congestive heart failure." | 9.08 | Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. ( Ajit-Uppal, J; Elkayam, U; Gogia, H; Johnson, JV; Mehra, A; Parikh, S; Raman, M, 1995) |
| "The effects of hydralazine plus isosorbide dinitrate were compared with those of enalapril in 804 men receiving digoxin and diuretic therapy for chronic congestive heart failure (CHF) in the Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trial (V-HeFT II)." | 9.07 | Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group. ( Carson, P; Cohn, JN; Francis, GS; Johnson, G, 1993) |
| "Male patients aged 18-75 years with chronic heart failure were randomized to enalapril or hydralazine-isosorbide dinitrate." | 9.07 | Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. ( Carson, P; Cintron, GB; Cohn, JN; Fletcher, RD; Johnson, G; Orndorff, J, 1993) |
| "To better define the effects of long-term vasodilator therapy on exercise performance in chronic congestive heart failure, we compared placebo with prazosin and with the combination of hydralazine and isosorbide dinitrate (Hyd-Iso) in 642 men over a 5-year period in V-HeFT I." | 9.07 | Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. ( Cobb, FR; Cohn, JN; Johnson, G; Tristani, F; Ziesche, S, 1993) |
| "Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate." | 9.07 | Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Daniels, G; Dunkman, WB; Farrell, L; Henrick, A; Johnson, G; Rector, TS; Smith, B, 1993) |
| "Despite better survival in patients randomized to hydralazine plus isosorbide dinitrate compared with placebo and better survival in patients randomized to enalapril compared with hydralazine plus isosorbide dinitrate, no significant differences between the treatment groups were apparent in the incidence of hospitalization or time to first hospitalization for congestive heart failure, for cardiac reasons other than congestive heart failure, or for other causes." | 9.07 | Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Cremo, R; Henrick, A; Johnson, G; Loeb, HS; Smith, R; Wilson, J, 1993) |
| "To compare the benefit of angiotensin-converting enzyme inhibition and direct vasodilation on the prognosis of advanced heart failure, 117 patients evaluated for cardiac transplantation who had severe symptoms and abnormal hemodynamic status at rest were randomized to treatment with either captopril or hydralazine plus isosorbide dinitrate (Hy-C Trial)." | 9.07 | Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. ( Albanese, E; Chelimsky-Fallick, C; Fonarow, GC; Hamilton, MA; Luu, M; Moriguchi, JD; Stevenson, LW; Tillisch, JH; Walden, JA, 1992) |
| " Fifty patients with symptoms due to chronic heart failure despite diuretic therapy were randomised to receive additional treatment with either hydralazine or captopril." | 9.07 | Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. ( Brooks, NH; Lawrence, GP; Schofield, PM; Testa, HJ; Ward, C, 1991) |
| "To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure." | 9.07 | A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. ( Cobb, F; Cohn, JN; Dunkman, WB; Francis, G; Johnson, G; Loeb, H; Smith, R; Tristani, F; Wong, M; Ziesche, S, 1991) |
| "The acute haemodynamic effects of intravenous nisoldipine and hydralazine were compared in nine patients with heart failure." | 9.06 | Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. ( Angel, ME; Haitas, B; Meyer, TE; Reef, E, 1990) |
| "We evaluated the effects of intravenous hydralazine (5 to 30 mg) and oral nifedipine (20 to 80 mg) on plasma catecholamines, renin, and aldosterone in 18 patients with severe chronic heart failure." | 9.06 | Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure. ( Elkayam, U; Freidenberger, L; Hsueh, W; Rahimtoola, SH; Roth, A; Weber, L, 1986) |
| "In a placebo-controlled trial 62 patients with chronic congestive heart failure (CHF) (New York Heart Association class III) had hydralazine (149 +/- 11 mg daily) or placebo added to conventional therapy." | 9.05 | Clinical efficacy of hydralazine in chronic heart failure: one-year double-blind placebo-controlled study. ( Ahlmark, G; Conradson, TB; Nyquist, O; Persson, S; Rydén, L; Saetre, H; Wernersson, B, 1984) |
| "The hemodynamic effect of venous dilatation (intravenous isosorbide dinitrate [ISDN]) and arteriolar dilatation (intravenous hydralazine), both as firstline treatment and then combined with intravenous furosemide, were evaluated in a randomized, between-group comparison in 20 men with severe acute left-sided cardiac failure after myocardial infarction (MI)." | 9.05 | Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction. ( Forsyth, DR; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1983) |
| "Hydralazine and isosorbide dinitrate can increase the cardiac output during submaximal exercise in patients with heart failure but whether this increase improves oxygen delivery to underperfused exercising muscle is uncertain." | 9.05 | Circulatory improvement after hydralazine or isosorbide dinitrate administration in patients with heart failure. Effect on metabolic responses to submaximal exercise. ( Ferraro, N; Wilson, JR, 1981) |
| "The use of direct acting vasodilators (the combination of hydralazine and isosorbide dinitrate -Hy+ISDN-) in heart failure with reduced ejection fraction (HFrEF) is supported by evidence, but rarely used." | 8.98 | Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction. ( Dékány, M; Muk, B; Nyolczas, N; Szabó, B, 2018) |
| "Hydralazine (H) and nitrates (Ns), when combined, reduced morbidity and mortality in some trials of chronic heart failure (CHF)." | 8.91 | Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. ( Clark, AL; Cleland, JG; Farag, M; Mabote, T; Nabhan, AF; Shoaib, A; Zhang, J, 2015) |
| "The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A)." | 8.90 | Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. ( Anand, I; Elkayam, U; Feldman, AM; Ferdinand, KC; Leggett, C; Mancini, D; McNamara, D; Ofili, E; Piña, I, 2014) |
| "The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057)." | 8.84 | Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure. ( Colvin-Adams, M; Taylor, AL, 2007) |
| " Search terms included hydralazine, drug-induced systemic lupus erythematosus, congestive heart failure, and antinuclear antibody." | 8.83 | Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. ( Finks, AL; Finks, SW; Self, TH, 2006) |
| "Articles or abstracts reporting the results of randomized, double-blind, controlled studies of ISDN and HYD in HF were identified through a search of the English-language literature indexed on MEDLINE and Current Contents/Clinical Medicine from 1966 to February 5, 2005, using the terms hydralazine, isosorbide dinitrate, nitrates, and heart failure." | 8.83 | A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. ( Cheng, JW, 2006) |
| "Hydralazine (1-hydrazinophthalazine) has been used extensively in the treatment of hypertension and congestive heart failure and produces arteriolar vasodilation, in part, mediated by prostaglandins." | 8.77 | Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure. ( Crawford, MH; Mulrow, JP, 1989) |
| "Underuse of hydralazine/nitrate (HYD/NIT) in black patients with heart failure and reduced ejection fraction (HFrEF) has been previously described, but whether this important treatment gap persists in contemporary practice is unknown." | 7.91 | Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). ( Adams, KF; Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Giblin, EM; Hernandez, AF; Hill, L; McCague, K; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB, 2019) |
| "The life-saving, guideline-recommended, adjunctive therapy for heart failure in African ancestry patients with hydralazine and isosorbide dinitrate is rarely used in Europe." | 7.91 | Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey. ( Brewster, LM, 2019) |
| "Hydralazine and nitrate combination was the first treatment that showed improved survival of patients with heart failure with reduced left ventricular ejection fraction (HFREF) in the Vasodilator Heart Failure Trial (V-HeFT trial) in 1986." | 7.91 | Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction. ( Al-Mohammad, A, 2019) |
| "Based upon the findings of the African-American Heart Failure Trial, the US Food and Drug Administration approved the fixed-dose combination of isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD) (FDC-ISDN/HYD) as a new drug for treatment of heart failure (HF) in self-identified African Americans." | 7.85 | Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure. ( Akinboboye, O; Anand, I; Ofili, E; Puckrein, G; Williams, RA; Xu, L, 2017) |
| "This study sought to evaluate the effectiveness of hydralazine-isosorbide dinitrate (H-ISDN) in African Americans with heart failure (HF) with reduced ejection fraction (HFrEF)." | 7.85 | Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure. ( Fonarow, GC; Heidenreich, PA; Ziaeian, B, 2017) |
| "In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with reduced ejection fraction reduced morbidity and mortality among black patients and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers." | 7.83 | Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. ( Bhatt, DL; Butler, J; Curtis, LH; Eapen, ZJ; Fonarow, GC; Heidenreich, PA; Hernandez, AF; Khazanie, P; Liang, L; Peterson, ED; Yancy, CW, 2016) |
| "The origins of the hydralazine/isosorbide dinitrate (H+ISDN) combination therapy are rooted in the first large-scale clinical trial in heart failure: V-HeFT I." | 7.80 | Current perspectives on hydralazine and nitrate therapies in heart failure. ( Butler, J; Cole, RT; Gupta, D, 2014) |
| "Hydralazine-isosorbide dinitrate (H-ISDN) therapy is recommended for African American patients with moderate to severe heart failure with reduced ejection fraction (<40%) (HFrEF), but use, temporal trends, and clinical characteristics associated with H-ISDN therapy in clinical practice are unknown." | 7.79 | Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. ( Bhatt, DL; Butler, J; Fonarow, GC; Golwala, HB; Hernandez, AF; Liang, L; Stavrakis, S; Thadani, U; Yancy, CW, 2013) |
| "Data supporting the use of oral isosorbide dinitrate and/or hydralazine (I/H) as add-on therapy to standard neurohormonal antagonists in advanced decompensated heart failure (ADHF) are limited, especially in the non-African-American population." | 7.75 | Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. ( Abrahams, Z; Francis, GS; Mullens, W; Sokos, G; Starling, RC; Tang, WH; Taylor, DO; Young, JB, 2009) |
| "The addition of hydralazine/isosorbide dinitrate (H-ISDN) to a standard heart failure treatment regimen in the African-American Heart Failure Trial was associated with a 43% reduction in mortality." | 7.75 | Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure. ( Emsermann, CB; Fairclough, D; Hamman, R; Hammermeister, KE; Ho, M; Phibbs, S; Plomondon, M; Steiner, JF; Valuck, R; West, D, 2009) |
| "To investigate if treatment with an aldosterone antagonist affects the outcomes of treatment by fixed dose combination of isosorbide dinitrate/hydralazine (FDC I/H) or placebo in black heart failure (HF) patients treated with contemporary HF medications." | 7.74 | Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial. ( Cohn, JN; Ghali, JK; Lindenfeld, J; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2008) |
| "This study sought to assess the effect of baseline systolic blood pressure (SBP) and changes in SBP on the effectiveness of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patients with heart failure (HF)." | 7.74 | Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. ( Adams, KF; Anand, IS; Archambault, WT; Cohn, JN; Olukotun, AY; Rector, TS; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2007) |
| "Fixed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved clinical outcomes in the African-American Heart Failure Trial (A-HeFT)." | 7.73 | Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. ( Angus, DC; Ghali, JK; Linde-Zwirble, WT; Sabolinski, ML; Tam, SW; Villagra, VG; Winkelmayer, WC; Worcel, M, 2005) |
| " Data were collected at baseline, after induction of heart failure (microsphere embolization into the left coronary artery), and then after toborinone boluses of 0." | 7.70 | Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure. ( Belenkie, I; Semeniuk, LM; Tyberg, JV, 1998) |
| " We assessed the effect of acute heart failure and the subsequent administration of hydralazine, enalaprilat, and nitroglycerin on the splanchnic venous pressure-volume relation in intact dogs." | 7.69 | Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin. ( Manyari, DE; Scott-Douglas, N; Smiseth, OA; Smith, ER; Tyberg, JV; Wang, SY, 1995) |
| "We investigated the effects of hydralazine on renal sympathetic nerve activity in anaesthetized heart failure rats." | 7.69 | Effects of hydralazine on renal sympathetic nerve activity in normal and congestive heart failure rats. ( Hedner, T; Sun, X; Thorén, P; Zhang, W; Zhao, X, 1997) |
| "Organic nitrates such as nitroglycerin and isosorbide dinitrate are useful in the treatment of congestive heart failure (CHF), but tolerance develops rapidly during continuous administration." | 7.68 | Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. ( Bauer, JA; Fung, HL, 1991) |
| "Nine male patients with stable chronic heart failure of different etiology and optimally treated with digoxine and diuretics were given hydralazine, 50 mg b." | 7.67 | Improved cardiac performance during exercise following hydralazine treatment in chronic heart failure. ( Conradson, TB; Rydén, L, 1984) |
| "The central and renal hemodynamic effects of nifedipine were evaluated in nine patients with severe chronic congestive heart failure." | 7.67 | Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure. ( Campese, VM; Elkayam, U; Massry, SG; Rahimtoola, SH; Weber, L, 1984) |
| "The hemodynamic response to a similar reduction of systemic vascular resistance after nifedipine and hydralazine administration was compared in a randomized crossover protocol in patients with severe chronic congestive heart failure (CHF)." | 7.67 | Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure. ( Elkayam, U; McKay, CR; Rahimtoola, SH; Weber, L, 1984) |
| "Changes in circulating catecholamines and transmyocardial catecholamine balance associated with improved left ventricular function were studied in patients with chronic heart failure after treatment with captopril (10 patients) and hydralazine in combination with isosorbide dinitrate (eight patients)." | 7.67 | Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure. ( Burgess, JH; Chatterjee, K; Cousineau, D; Daly, P; Rouleau, JL, 1986) |
| "2 mg propranolol intravenously resulted in acute pulmonary edema." | 7.67 | Severe hypertension, propranolol, and acute pulmonary edema. ( Desai, SP; Fleming, TC; Pierce, EC, 1987) |
| "The mechanism by which hydralazine improves cardiac function in patients with heart failure is not well characterized." | 7.67 | Effects of hydralazine on pressure-volume and stress-volume relations in congestive heart failure secondary to idiopathic dilated cardiomyopathy. ( Lipscomb, KM; Sanford, CF; Smucker, ML, 1985) |
| "Short-term therapy with oral hydralazine can favorably affect abnormal hemodynamics in patients with congestive heart failure, but the range of dosage is large." | 7.67 | Determinants of systemic availability of oral hydralazine in heart failure. ( Crawford, MH; Kennedy, GT; Ludden, TM, 1985) |
| "The oral angiotensin-converting enzyme inhibitor captopril (CPT) produces beneficial hemodynamic and clinical responses in patients with chronic congestive heart failure (CHF)." | 7.66 | Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost. ( Chatterjee, K; Parmley, WW; Rouleau, JL, 1982) |
| "Simultaneous hemodynamic and radionuclide angiographic assessment was made at rest and during exercise in nine patients with severe chronic congestive heart failure to determine the value of radionuclide left ventricular ejection fraction measurement in predicting the hemodynamic response to short-term treatment with oral hydralazine." | 7.66 | Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response. ( Franklin, BA; Goldberg, MJ; Kerin, NZ; Rubenfire, M; Ruskin, R; Willens, HJ, 1983) |
| "The hemodynamic benefits and safety of combined therapy with captopril and hydralazine were studied during invasive hemodynamic monitoring in 14 patients with severe heart failure." | 7.66 | Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. ( Combs, DT; Hanlon, JT; Massie, BM; Packer, M, 1983) |
| "We studied the hemodynamic response to orally administered hydralazine (30 mg) and examined the changes in neurohumoral factors in 16 aged patients with chronic congestive heart failure." | 7.66 | Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure. ( Kuwajima, I; Matsushita, S; Murakami, M; Sakai, M; Ueda, K, 1983) |
| "The influence of various disease states, other than hypertension, on the pharmacokinetic behaviour of hydralazine is not completely known." | 7.66 | Pharmacokinetics of oral hydralazine in chronic heart failure. ( Hanson, A; Johansson, BW; Wåhlander, LA; Wernersson, B, 1983) |
| "Four studies were conducted in 36 patients with severe chronic heart failure to compare the central hemodynamic effects of captopril (CPT) to other vasodilator agents." | 7.66 | Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs. ( Medina, N; Packer, M; Yushak, M, 1982) |
| " We compared the acute haemodynamic effects of captopril and hydralazine in 11 patients with congestive cardiac failure unresponsive to diuretics and digoxin." | 7.66 | Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction. ( Fitzgerald, DJ; Horgan, J; O'Brien, E; O'Callaghan, WG; O'Malley, K, 1982) |
| "Supine and upright hemodynamic measurements were performed in 10 patients with chronic congestive heart failure, before and during vasodilator therapy with hydralazine and isosorbide dinitrate." | 7.66 | Postural hypotension and tachycardia during hydralazine--isosorbide dinitrate therapy for chronic heart failure. ( Haughom, F; Kramer, B; Massie, B, 1981) |
| "Coronary blood flow and myocardial energetics were assessed after the administration of a parenteral inotrope (dobutamine hydrochloride) and an oral vasodilator agent (hydralazine) in 10 patients with nonischemic congestive heart failure." | 7.66 | Dobutamine and hydralazine: comparative influences of positive inotropy and vasodilation on coronary blood flow and myocardial energetics in nonischemic congestive heart failure. ( Brown, GP; Leier, CV; Magorien, RD; Unverferth, DV, 1983) |
| "To determine whether the circulatory response to hydralazine in heart failure is influenced by initial hemodynamic status or left ventricular (LV) chamber size, 28 patients with chronic LV dysfunction were studied." | 7.66 | Determinants of circulatory response to intravenous hydralazine in congestive heart failure. ( Ferraro, N; Reichek, N; Schwartz, JS; St John Sutton, M; Wilson, JR, 1983) |
| "The acute effects of oral hydralazine, 1 mg/kg, on coronary vascular resistance, coronary blood flow (estimated using the coronary sinus thermodilution technique), and myocardial oxygen consumption were evaluated in 10 patients with chronic (New York Heart Association class III and IV) nonischemic congestive heart failure." | 7.66 | Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure. ( Bambach, D; Boudoulas, H; Brown, GP; Leier, CV; Magorien, RD; Nelson, S; Unverferth, DV, 1982) |
| "The effects of dipyridamole, a coronary and peripheral vasodilator drug, on cardiac performance were investigated in nine patients with severe chronic heart failure." | 7.66 | Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine. ( Gorlin, R; Medina, N; Meller, J; Packer, M, 1982) |
| "Eleven dogs with mitral regurgitation and severe cough were given hydralazine for reduction of systemic arterial pressure." | 7.66 | Clinical experience with hydralazine for treatment of otherwise intractable cough in dogs with apparent left-side heart failure. ( Hamlin, RL; Kittleson, MD, 1982) |
| "Several reports have suggested that because isosorbide dinitrate and hydralazine have different and additive haemodynamic effects at rest in patients with chronic heart failure, these agents should be administered in combination." | 7.66 | Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure. ( Haughom, F; Kramer, B; Massie, BM; Shen, E, 1981) |
| "The hemodynamic effects of oral doses of prazosin and hydralazine were studied in the same group of patients with chronic congestive heart failure." | 7.66 | Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure. ( Elkayam, U; Frishman, W; LeJemtel, T; Mathur, M; Sonnenblick, EH; Strom, J, 1981) |
| "Central hemodynamic variables and regional blood flow and vascular resistances were ascertained in patients with severe congestive heart failure before and after the oral administration of prazosin hydrochloride or hydralazine." | 7.66 | Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. ( Bay, WH; Desch, CE; Leier, CV; Magorien, RD; Triffon, DW; Unverferth, DV, 1981) |
| "The diuretic effect of furosemide was studied in 18 patients with congestive heart failure." | 7.66 | Effect of furosemide in congestive heart failure. ( Akimoto, T; Arita, T; Minami, M; Miyazaki, K; Nomura, A; Yasuda, H, 1981) |
| "The hemodynamic benefits of combined administration of prenalterol (P) with hydralazine (H) were evaluated in ten patients with severe chronic heart failure." | 7.66 | Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure. ( Drexler, H; Just, H; Löllgen, H, 1981) |
| "We studied the effect of vasodilator therapy on renal digoxin clearance in patients with chronic congestive heart failure." | 7.66 | Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. ( Benowitz, NL; Carlson, CJ; Cogan, JJ; Humphreys, MH; Rapaport, E, 1981) |
| "The acute effects of nitroprusside infusion and intravenous hydralazine on renal hemodynamics and function were evaluated in nine male patients with severe, low cardiac output, congestive heart failure (CHF)." | 7.66 | Renal effects of nitroprusside and hydralazine in patients with congestive heart failure. ( Carlson, CJ; Cogan, JJ; Humphreys, MH; Rapaport, E, 1980) |
| "Hemodynamic responses to different doses of hydralazine were evaluated in 18 patients with severe refractory resistant heart failure." | 7.66 | Hemodynamic evaluation of hydralazine dosage in refractory heart failure. ( Gorlin, R; Herman, MV; Medina, N; Meller, J; Packer, M, 1980) |
| "To examine the importance of left ventricular chamber size in determing the response to vasodilator therapy, we performed echocardiography in 40 patients with chronic refractory heart failure before they were treated with oral hydralazine." | 7.66 | Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. ( Gorlin, R; Herman, MV; Medina, N; Meller, J; Packer, M, 1980) |
| "Hemodynamic effects of oral hydralazine (200 to 400 mg/d) were evaluated in 11 patients with chronic heart failure after short-term (24 hours) and long-term (average, 8." | 7.66 | Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects. ( Brundage, BH; Chatterjee, K; Holly, AN; Massie, B; Parmley, WW; Ports, TA, 1980) |
| "Nifedipine, a potent coronary vasodilator, was administered in a single sublingual dose of 20 mg to eight patients with mild to moderate congestive heart failure." | 7.66 | Hemodynamic effects of nifedipine in congestive heart failure. ( Ito, T; Ito, Y; Matsumoto, S; Okabe, F; Sada, T; Sato, M; Sekine, I; Su, KM; Takahashi, M; Ueda, A, 1980) |
| " To determine whether this vasodilator elicits a positive inotropic response in the failing human ventricle, hydralazine, 75 or 100 mg, was administered orally to 14 patients with left ventricular dysfunction and congestive heart failure; the results were compared with those of first-dose prazosin at 5 and 10 mg." | 7.66 | Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure. ( Boudoulas, H; Desch, CE; Leier, CV; Lewis, RP; Magorien, RD; Triffon, DW; Unverferth, DV, 1980) |
| "In order to develop a noninvasive means for following left ventricular responses to hydralazine, we measured the systolic time intervals serially in 6 patients with heart failure." | 7.66 | Noninvasive assessment of left ventricular effects of hydralazine in heart failure. ( Deglin, SM; Harris, WS; Jain, AC, 1980) |
| "Sudden withdrawal of oral therapy with hydralazine for reduction of afterload in a patient precipitated severe congestive heart failure." | 7.66 | Precipitation of heart failure following sudden withdrawal of hydralazine. ( Black, JR; Mehta, J, 1979) |
| "Changes in left ventricular performance were evaluated in 14 patients with functional New York Heart Association class III or IV chronic heart failure before and after the addition of oral hydralazine to conventional therapy." | 7.66 | Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure. ( Brundage, BH; Chatterjee, K; Gelberg, HJ; Parmley, WW; Ports, TA; Rubin, SA, 1979) |
| "The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure." | 7.66 | Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979) |
| "The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients." | 7.66 | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979) |
| "Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates." | 7.66 | Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy. ( Amsterdam, EA; DeMaria, AN; Laslett, LJ; Mason, DT, 1978) |
| "The hemodynamic effects of oral hydralazine were investigated in ten patients (nine in NYHA Class IV and one in Class III) with chronic refractory heart failure." | 7.65 | Oral hydralazine therapy for chronic refractory heart failure. ( Chatterjee, K; Greenberg, B; Klausner, S; Massie, B; Norman, A; Parmley, WW; Werner, J, 1976) |
| "Treatment with hydralazine-nitrate produced a 28% reduction in mortality compared with that in patients receiving placebo (95% confidence interval, 3% to 46%), whereas prazosin exerted no apparent beneficial effect." | 6.66 | Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. ( Archibald, DG; Cohn, JN; Dunkman, WB; Flohr, KH; Franciosa, JA; Francis, GS; Harston, WE; Jacobs, W; Tristani, FE; Ziesche, S, 1987) |
| "Congestive heart failure is accompanied by a number of compensatory mechanisms that may overshoot the mark." | 6.37 | Role of isosorbide dinitrate in management of chronic congestive heart failure. ( Parmley, WW, 1985) |
| "Hydralazine is a smooth muscle relaxant and a potent arteriolar dilator." | 6.36 | Hydralazine in heart failure. ( Chatterjee, K, 1983) |
| "Treatment with sodium nitrite and hydralazine restored NO bioavailability, reduced oxidative and nitrosative stress, preserved endothelial function and mitochondrial respiration, limited the fibrotic response, and improved exercise capacity, ultimately attenuating the severity of "two-hit" HFpEF." | 5.91 | Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a "2-Hit" Murine Model. ( Doiron, JE; Goodchild, TT; Koul, K; LaPenna, KB; Lefer, DJ; Li, Z; Moles, K; Patel, RB; Polhemus, DJ; Shah, SJ; Sharp, TE; Wang, JS; Xia, H, 2023) |
| "Captopril patients were matched 1:2 to H-ISDN patients, based on serum creatinine and race (Black vs non-Black)." | 5.62 | Captopril Versus Hydralazine-Isosorbide Dinitrate Vasodilator Protocols in Patients With Acute Decompensated Heart Failure Transitioning From Sodium Nitroprusside. ( Amar, M; Faulkenberg, K; Lam, SW; Perez, A; Tang, WHW; Williams, JB, 2021) |
| "Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate (GMP) pathway." | 5.62 | Vericiguat, organic nitrates, and heart failure in African Americans. ( Guglin, M; Ilonze, OJ, 2021) |
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 5.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "To investigate the effects of hydralazine combined with nitrate on serum levels of Adropin and brain natriuretic peptide (BNP), left ventricular remodeling and prognosis in patients with chronic heart failure (CHF)." | 5.41 | Combined effects of hydralazine and nitrate on serum biochemistry and left ventricular remodeling in chronic heart failure patients. ( Lu, Y; Qian, L; Xu, W; Yuan, X, 2021) |
| " Experimental data suggests that hydralazine, given concomitantly, attenuates the development of hemodynamic tolerance to ISDN and may increase bioavailability of NO in the vasculature." | 5.35 | Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. ( Jacob, RG; Thadani, U, 2008) |
| "Systolic heart failure is a condition that exerts a devastating toll on those affected." | 5.34 | Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure. ( Flack, JM, 2007) |
| "Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of this compound." | 5.33 | Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. ( Bachschmid, M; Coldewey, M; Daiber, A; Huth, C; Kaiser, K; Mülsch, A; Münzel, T; Nazirisadeh, Y; Oelze, M; Schildknecht, S; Tsilimingas, N; Ullrich, V, 2005) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 5.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Each infant had congestive heart failure and angiographic evidence of markedly depressed left ventricular ejection fraction (0." | 5.27 | Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure. ( Appleton, S; Artman, M; Boucek, RJ; Graham, TP; Parrish, MD, 1987) |
| "Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure." | 5.22 | A review on the clinical pharmacokinetics of hydralazine. ( Alqahtani, F; Ashraf, W; Hussain, I; Imran, I; Khalid, S; Majeed, A; Rasool, MF; Rehman, AU; Saeed, H; Shahzad Qamar, A; Zamir, A, 2022) |
| "Patients with acute heart failure (HF) in Africa are rarely being treated with a hydralazine/nitrates combination." | 5.22 | Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF). ( Ba, SA; Cotter, G; Damasceno, A; Davison, BA; Dzudie, A; Edwards, C; Kouam, CK; Mayosi, BM; Milo, O; Mondo, C; Ogah, O; Ogola, E; Ojji, D; Sani, MU; Sliwa, K; Yonga, G, 2016) |
| "Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hospitalization for heart failure (HF) by 37% in the African-American Heart Failure Trial (A-HeFT)." | 5.19 | Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial. ( Anand, IS; Cohn, JN; Rector, TS; Taylor, AL; Win, S, 2014) |
| "The purpose of this study was to evaluate the influence of the guanine nucleotide-binding proteins (G-proteins), beta-3 subunit (GNB3) genotype on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in A-HeFT (African American Heart Failure Trial)." | 5.19 | G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. ( Cohn, JN; Feldman, AM; Hanley-Yanez, K; McNamara, DM; Tam, SW; Taylor, AL; Worcel, M; Yancy, CW, 2014) |
| "Sixteen older persons free of known cardiovascular disease with the exception of hypertension had noninvasive tonometry and cardiac ultrasound to evaluate central augmentation index (AI) and diastolic function at baseline and after randomized, blinded administration of intravenous B-type natriuretic peptide (BNP) and hydralazine in a crossover design." | 5.17 | Left ventricular responses to acute changes in late systolic pressure augmentation in older adults. ( Eggleston, K; Hetzel, SJ; Mitchell, GF; Skalski, J; Sweitzer, NK; Velez, M, 2013) |
| "Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) significantly improved outcomes in patients with advanced heart failure (HF) receiving background neurohormonal therapy in the African-American Heart Failure Trial (A-HeFT)." | 5.16 | Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. ( Archambault, WT; Cohn, JN; Ghali, JK; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M; Ziesche, S, 2012) |
| "The A-HeFT trial demonstrated incremental survival with hydralazine/isosorbide dinitrate combination in African-American patients with chronic heart failure (CHF)." | 5.14 | Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure. ( Chirkov, YY; De Sciscio, M; Horowitz, JD; Leslie, S; Sage, PR; Sverdlov, AL, 2010) |
| "Hydralazine, an arterial vasodilator, is a widely used medication for the management of hypertension and heart failure, especially for patients who cannot tolerate the use of ACEIs or ARBs." | 5.12 | Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review. ( Al-Sadawi, M; Battisha, A; Doughem, K; Konduru, L; Madoukh, B; Shaikh, S; Sheikh, O, 2021) |
| "We previously reported that the fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC I/H) significantly decreased the risk of all-cause death and first hospitalization for heart failure (HF) and improved quality of life in patients with New York Heart Association class III or IV heart failure in the African-American Heart Failure Trial (A-HeFT)." | 5.12 | Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. ( Adams, K; Carson, P; Cohn, JN; Ferdinand, K; Ofili, E; Olukotun, AY; Sabolinski, ML; Tam, SW; Taylor, AL; Taylor, M; Worcel, M; Yancy, CW; Ziesche, S, 2007) |
| "Isosorbide dinitrate combined with hydralazine therapy compared with placebo in patients with heart failure resulted in a sustained increase in left ventricular (LV) ejection fraction (EF) indicative of regression of LV remodeling in the first Vasodilator-Heart Failure Trial (V-HeFT-I) in patients receiving only digoxin and diuretic." | 5.12 | Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. ( Anand, IS; Cohn, JN; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2007) |
| "The benefits of fixed-dose combination isosorbide dinitrate plus hydralazine (ID/H) in African-Americans with heart failure (HF) were established by the African-American Heart Failure Trial (A-HeFT), which was terminated early because of a significant survival benefit of ID/H." | 5.12 | Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). ( Archambault, WT; Braman, VM; Franciosa, JA; Ghali, JK; Sabolinski, ML; Worcel, M; Yancy, CW, 2007) |
| "In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved patient reported functional status compared with standard therapy alone." | 5.12 | Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. ( Cohn, JN; Curry, CL; Ferdinand, KC; Ghali, JK; Lindenfeld, J; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2007) |
| "We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy." | 5.11 | Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. ( Adams, K; Carson, P; Cohn, JN; D'Agostino, R; Ferdinand, K; Sabolinski, M; Taylor, AL; Taylor, M; Worcel, M; Yancy, C; Ziesche, S, 2004) |
| "Hydralazine and isosorbide dinitrate combination (H+ISDN), angiotensin-converting enzyme inhibitors, and beta-blockers have improved outcomes in heart failure (HF)." | 5.10 | African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. ( Cohn, JN; Ferdinand, K; Franciosa, JA; Loscalzo, J; Ofili, E; Olukotun, A; Taylor, AL; Worcel, M; Yancy, CW; Ziesche, S, 2002) |
| "This study was designed to determine the effect of oral hydralazine on the development of nitrate tolerance in patients with chronic congestive heart failure." | 5.08 | Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. ( Ajit-Uppal, J; Elkayam, U; Gogia, H; Johnson, JV; Mehra, A; Parikh, S; Raman, M, 1995) |
| "We compared the effects of Hydralazine and Isosorbide dinitrate (ISDN) with those of an angiotensin-converting-enzyme inhibitor, captopril on mortality in patients with chronic congestive heart failure (NYHA class III and IV)." | 5.07 | Effect of vasodilator therapy on mortality in chronic congestive heart failure. ( Bhandari, B; Chakraborty, S; Ghose, JC; Mondal, M, 1993) |
| "The effects of hydralazine plus isosorbide dinitrate were compared with those of enalapril in 804 men receiving digoxin and diuretic therapy for chronic congestive heart failure (CHF) in the Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trial (V-HeFT II)." | 5.07 | Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group. ( Carson, P; Cohn, JN; Francis, GS; Johnson, G, 1993) |
| "Male patients aged 18-75 years with chronic heart failure were randomized to enalapril or hydralazine-isosorbide dinitrate." | 5.07 | Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. ( Carson, P; Cintron, GB; Cohn, JN; Fletcher, RD; Johnson, G; Orndorff, J, 1993) |
| "To better define the effects of long-term vasodilator therapy on exercise performance in chronic congestive heart failure, we compared placebo with prazosin and with the combination of hydralazine and isosorbide dinitrate (Hyd-Iso) in 642 men over a 5-year period in V-HeFT I." | 5.07 | Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. ( Cobb, FR; Cohn, JN; Johnson, G; Tristani, F; Ziesche, S, 1993) |
| "Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate." | 5.07 | Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Daniels, G; Dunkman, WB; Farrell, L; Henrick, A; Johnson, G; Rector, TS; Smith, B, 1993) |
| "Despite better survival in patients randomized to hydralazine plus isosorbide dinitrate compared with placebo and better survival in patients randomized to enalapril compared with hydralazine plus isosorbide dinitrate, no significant differences between the treatment groups were apparent in the incidence of hospitalization or time to first hospitalization for congestive heart failure, for cardiac reasons other than congestive heart failure, or for other causes." | 5.07 | Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Cremo, R; Henrick, A; Johnson, G; Loeb, HS; Smith, R; Wilson, J, 1993) |
| "The incidence of thromboembolism and stroke in class II or III congestive heart failure is not high and may not be significantly reduced with warfarin treatment." | 5.07 | Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. ( Bhat, G; Carson, PE; Cohn, JN; Dunkman, WB; Farrell, L; Johnson, GR, 1993) |
| "To compare the benefit of angiotensin-converting enzyme inhibition and direct vasodilation on the prognosis of advanced heart failure, 117 patients evaluated for cardiac transplantation who had severe symptoms and abnormal hemodynamic status at rest were randomized to treatment with either captopril or hydralazine plus isosorbide dinitrate (Hy-C Trial)." | 5.07 | Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. ( Albanese, E; Chelimsky-Fallick, C; Fonarow, GC; Hamilton, MA; Luu, M; Moriguchi, JD; Stevenson, LW; Tillisch, JH; Walden, JA, 1992) |
| " Fifty patients with symptoms due to chronic heart failure despite diuretic therapy were randomised to receive additional treatment with either hydralazine or captopril." | 5.07 | Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. ( Brooks, NH; Lawrence, GP; Schofield, PM; Testa, HJ; Ward, C, 1991) |
| "To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure." | 5.07 | A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. ( Cobb, F; Cohn, JN; Dunkman, WB; Francis, G; Johnson, G; Loeb, H; Smith, R; Tristani, F; Wong, M; Ziesche, S, 1991) |
| "The acute haemodynamic effects of intravenous nisoldipine and hydralazine were compared in nine patients with heart failure." | 5.06 | Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. ( Angel, ME; Haitas, B; Meyer, TE; Reef, E, 1990) |
| "We evaluated the effects of intravenous hydralazine (5 to 30 mg) and oral nifedipine (20 to 80 mg) on plasma catecholamines, renin, and aldosterone in 18 patients with severe chronic heart failure." | 5.06 | Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure. ( Elkayam, U; Freidenberger, L; Hsueh, W; Rahimtoola, SH; Roth, A; Weber, L, 1986) |
| "The reduction of mortality in patients with chronic congestive heart failure treated with the vasodilator regimen hydralazine and isosorbide dinitrate compared to those treated with placebo or prazosin in the Veterans Administration Cooperative Study (V-HeFT) was examined in order to explore the possible mechanism of the favourable effect." | 5.06 | Effect of vasodilator therapy on mortality in chronic congestive heart failure. ( Cohn, JN, 1988) |
| "To evaluate the effects of vasodilator therapy on mortality among patients with chronic congestive heart failure, we randomly assigned 642 men with impaired cardiac function and reduced exercise tolerance who were taking digoxin and a diuretic to receive additional double-blind treatment with placebo, prazosin (20 mg per day), or the combination of hydralazine (300 mg per day) and isosorbide dinitrate (160 mg per day)." | 5.06 | Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. ( Archibald, DG; Cohn, JN; Dunkman, WB; Flohr, KH; Franciosa, JA; Francis, GS; Harston, WE; Jacobs, W; Tristani, FE; Ziesche, S, 1986) |
| "In a placebo-controlled trial 62 patients with chronic congestive heart failure (CHF) (New York Heart Association class III) had hydralazine (149 +/- 11 mg daily) or placebo added to conventional therapy." | 5.05 | Clinical efficacy of hydralazine in chronic heart failure: one-year double-blind placebo-controlled study. ( Ahlmark, G; Conradson, TB; Nyquist, O; Persson, S; Rydén, L; Saetre, H; Wernersson, B, 1984) |
| "The hemodynamic effect of venous dilatation (intravenous isosorbide dinitrate [ISDN]) and arteriolar dilatation (intravenous hydralazine), both as firstline treatment and then combined with intravenous furosemide, were evaluated in a randomized, between-group comparison in 20 men with severe acute left-sided cardiac failure after myocardial infarction (MI)." | 5.05 | Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction. ( Forsyth, DR; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1983) |
| "Hydralazine and isosorbide dinitrate can increase the cardiac output during submaximal exercise in patients with heart failure but whether this increase improves oxygen delivery to underperfused exercising muscle is uncertain." | 5.05 | Circulatory improvement after hydralazine or isosorbide dinitrate administration in patients with heart failure. Effect on metabolic responses to submaximal exercise. ( Ferraro, N; Wilson, JR, 1981) |
| "The acute haemodynamic effects of 40 mg isosorbide dinitrate (10 subjects), 4 mg prazosin (20 subjects) and 50 mg dihydralazine (8 subjects) were compared in 24 patients with the clinical picture of chronic therapy-resistant cardiac failure (NY Heart Association stages III-IV)." | 5.05 | [Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)]. ( Himmler, FC; Klein, G; Kutschera, I; Sauer, E; Schmidt, G; Wirtzfeld, A, 1980) |
| "The use of direct acting vasodilators (the combination of hydralazine and isosorbide dinitrate -Hy+ISDN-) in heart failure with reduced ejection fraction (HFrEF) is supported by evidence, but rarely used." | 4.98 | Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction. ( Dékány, M; Muk, B; Nyolczas, N; Szabó, B, 2018) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| "Hydralazine (H) and nitrates (Ns), when combined, reduced morbidity and mortality in some trials of chronic heart failure (CHF)." | 4.91 | Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. ( Clark, AL; Cleland, JG; Farag, M; Mabote, T; Nabhan, AF; Shoaib, A; Zhang, J, 2015) |
| "The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A)." | 4.90 | Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. ( Anand, I; Elkayam, U; Feldman, AM; Ferdinand, KC; Leggett, C; Mancini, D; McNamara, D; Ofili, E; Piña, I, 2014) |
| "Organic nitrates still are one of the most important drug classes used in the treatment of an acute coronary syndrome and stable coronary artery disease as well as acute and chronic congestive heart failure." | 4.84 | [Recent findings on nitrates: their action, bioactivation and development of tolerance]. ( Münzel, T, 2008) |
| "The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057)." | 4.84 | Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure. ( Colvin-Adams, M; Taylor, AL, 2007) |
| " Search terms included hydralazine, drug-induced systemic lupus erythematosus, congestive heart failure, and antinuclear antibody." | 4.83 | Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. ( Finks, AL; Finks, SW; Self, TH, 2006) |
| "Articles or abstracts reporting the results of randomized, double-blind, controlled studies of ISDN and HYD in HF were identified through a search of the English-language literature indexed on MEDLINE and Current Contents/Clinical Medicine from 1966 to February 5, 2005, using the terms hydralazine, isosorbide dinitrate, nitrates, and heart failure." | 4.83 | A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. ( Cheng, JW, 2006) |
| " Digoxin has not been shown to affect the natural history of heart failure and should be reserved for patients who remain symptomatic after treatment with ACE inhibitors and diuretics." | 4.79 | Management of heart failure. I. Pharmacologic treatment. ( Baker, DW; Bottorff, M; Konstam, MA; Pitt, B, 1994) |
| "Hydralazine (1-hydrazinophthalazine) has been used extensively in the treatment of hypertension and congestive heart failure and produces arteriolar vasodilation, in part, mediated by prostaglandins." | 4.77 | Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure. ( Crawford, MH; Mulrow, JP, 1989) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| "Underuse of hydralazine/nitrate (HYD/NIT) in black patients with heart failure and reduced ejection fraction (HFrEF) has been previously described, but whether this important treatment gap persists in contemporary practice is unknown." | 3.91 | Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). ( Adams, KF; Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Giblin, EM; Hernandez, AF; Hill, L; McCague, K; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB, 2019) |
| "The life-saving, guideline-recommended, adjunctive therapy for heart failure in African ancestry patients with hydralazine and isosorbide dinitrate is rarely used in Europe." | 3.91 | Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey. ( Brewster, LM, 2019) |
| "Hydralazine and nitrate combination was the first treatment that showed improved survival of patients with heart failure with reduced left ventricular ejection fraction (HFREF) in the Vasodilator Heart Failure Trial (V-HeFT trial) in 1986." | 3.91 | Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction. ( Al-Mohammad, A, 2019) |
| "The evidence-based heart failure (HF) drug treatment is made of a β-blocker and an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, or hydralazine + isosorbide dinitrate." | 3.88 | Adherence to the evidence-based heart failure drug treatment: Are there sex-specific differences among new users? ( Demers, E; Girouard, C; Grégoire, JP; Kayibanda, JF; Moisan, J, 2018) |
| "Based upon the findings of the African-American Heart Failure Trial, the US Food and Drug Administration approved the fixed-dose combination of isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD) (FDC-ISDN/HYD) as a new drug for treatment of heart failure (HF) in self-identified African Americans." | 3.85 | Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure. ( Akinboboye, O; Anand, I; Ofili, E; Puckrein, G; Williams, RA; Xu, L, 2017) |
| "This study sought to evaluate the effectiveness of hydralazine-isosorbide dinitrate (H-ISDN) in African Americans with heart failure (HF) with reduced ejection fraction (HFrEF)." | 3.85 | Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure. ( Fonarow, GC; Heidenreich, PA; Ziaeian, B, 2017) |
| "In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with reduced ejection fraction reduced morbidity and mortality among black patients and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers." | 3.83 | Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. ( Bhatt, DL; Butler, J; Curtis, LH; Eapen, ZJ; Fonarow, GC; Heidenreich, PA; Hernandez, AF; Khazanie, P; Liang, L; Peterson, ED; Yancy, CW, 2016) |
| "The origins of the hydralazine/isosorbide dinitrate (H+ISDN) combination therapy are rooted in the first large-scale clinical trial in heart failure: V-HeFT I." | 3.80 | Current perspectives on hydralazine and nitrate therapies in heart failure. ( Butler, J; Cole, RT; Gupta, D, 2014) |
| "Hydralazine-isosorbide dinitrate (H-ISDN) therapy is recommended for African American patients with moderate to severe heart failure with reduced ejection fraction (<40%) (HFrEF), but use, temporal trends, and clinical characteristics associated with H-ISDN therapy in clinical practice are unknown." | 3.79 | Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. ( Bhatt, DL; Butler, J; Fonarow, GC; Golwala, HB; Hernandez, AF; Liang, L; Stavrakis, S; Thadani, U; Yancy, CW, 2013) |
| "Combination therapy with hydralazine and nitrates can improve outcomes in patients with heart failure and low ejection fraction." | 3.79 | Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. ( Butler, J; Fonarow, GC; Georgiopoulou, VV; Gheorghiade, M; Gupta, D; Kalogeropoulos, AP; Konstam, MA; Marti, CN; Yancy, CW, 2013) |
| "Data supporting the use of oral isosorbide dinitrate and/or hydralazine (I/H) as add-on therapy to standard neurohormonal antagonists in advanced decompensated heart failure (ADHF) are limited, especially in the non-African-American population." | 3.75 | Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. ( Abrahams, Z; Francis, GS; Mullens, W; Sokos, G; Starling, RC; Tang, WH; Taylor, DO; Young, JB, 2009) |
| "The addition of hydralazine/isosorbide dinitrate (H-ISDN) to a standard heart failure treatment regimen in the African-American Heart Failure Trial was associated with a 43% reduction in mortality." | 3.75 | Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure. ( Emsermann, CB; Fairclough, D; Hamman, R; Hammermeister, KE; Ho, M; Phibbs, S; Plomondon, M; Steiner, JF; Valuck, R; West, D, 2009) |
| " Food and Drug Administration's (FDA) rationale for supporting the development and approval of BiDil (a combination of hydralazine hydrochloride and isosorbide dinitrate; H-I) for heart failure specifically in black patients was based on under-powered, post hoc subgroup analyses of two relatively old trials (V-HeFT I and II), which were further complicated by substantial covariate imbalances between racial groups." | 3.74 | Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients. ( Ellison, GT; Head, RF; Kahn, JD; Kaufman, JS; Martin, PA, 2008) |
| "To investigate if treatment with an aldosterone antagonist affects the outcomes of treatment by fixed dose combination of isosorbide dinitrate/hydralazine (FDC I/H) or placebo in black heart failure (HF) patients treated with contemporary HF medications." | 3.74 | Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial. ( Cohn, JN; Ghali, JK; Lindenfeld, J; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2008) |
| "5 mg, and isosorbide dinitrate, 20 mg, for treating heart failure in black patients have suggested that data were insufficient to distinguish treatment effects in black and white people; that distinctions based on race, rather than pathophysiology, were scientifically unreasonable; and that a "race-based" approval could be a commercial ploy to avoid a more expensive and prolonged full evaluation of a drug." | 3.74 | BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective. ( Stockbridge, NL; Temple, R, 2007) |
| "This study sought to assess the effect of baseline systolic blood pressure (SBP) and changes in SBP on the effectiveness of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patients with heart failure (HF)." | 3.74 | Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. ( Adams, KF; Anand, IS; Archambault, WT; Cohn, JN; Olukotun, AY; Rector, TS; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M, 2007) |
| "Fixed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved clinical outcomes in the African-American Heart Failure Trial (A-HeFT)." | 3.73 | Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. ( Angus, DC; Ghali, JK; Linde-Zwirble, WT; Sabolinski, ML; Tam, SW; Villagra, VG; Winkelmayer, WC; Worcel, M, 2005) |
| "The A-HeFT (African American Heart Failure Trial) showed that isosorbide/hydralazine was associated with significant reductions in mortality in African Americans with heart failure compared with placebo." | 3.73 | Should drug therapy be personalized based on race? ( Vivian, EM, 2006) |
| " Data were collected at baseline, after induction of heart failure (microsphere embolization into the left coronary artery), and then after toborinone boluses of 0." | 3.70 | Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure. ( Belenkie, I; Semeniuk, LM; Tyberg, JV, 1998) |
| " We assessed the effect of acute heart failure and the subsequent administration of hydralazine, enalaprilat, and nitroglycerin on the splanchnic venous pressure-volume relation in intact dogs." | 3.69 | Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin. ( Manyari, DE; Scott-Douglas, N; Smiseth, OA; Smith, ER; Tyberg, JV; Wang, SY, 1995) |
| "Hydralazine has been shown to reduce mortality in patients with congestive heart failure when given concomitantly with isosorbide dinitrate." | 3.69 | Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. ( Berrington, WR; Freeman, BA; Harrison, DG; Kurz, S; Münzel, T; Rajagopalan, S; Thoenes, M; Thompson, JA, 1996) |
| "We investigated the effects of hydralazine on renal sympathetic nerve activity in anaesthetized heart failure rats." | 3.69 | Effects of hydralazine on renal sympathetic nerve activity in normal and congestive heart failure rats. ( Hedner, T; Sun, X; Thorén, P; Zhang, W; Zhao, X, 1997) |
| "Organic nitrates such as nitroglycerin and isosorbide dinitrate are useful in the treatment of congestive heart failure (CHF), but tolerance develops rapidly during continuous administration." | 3.68 | Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. ( Bauer, JA; Fung, HL, 1991) |
| " A Veterans Administration (VA) cooperative study published in June 1986 showed that congestive heart failure (CHF) patients who had hydralazine and isosorbide added to their drug therapy had less mortality than patients given digoxin and diuretics with or without prazosin." | 3.68 | Impact of a drug-use review program intervention on prescribing after publication of a randomized clinical trial. ( Bjornson, DC; Daniels, CE; Litman, TJ; Rector, TS; Snowdon, DA; Wertheimer, AI, 1990) |
| "To determine the effects of vasodilator and inotropic therapy on hyponatremia in patients with severe heart failure, we measured serum sodium concentration before and after treatment with captopril (70 patients), hydralazine (42 patients), prazosin (22 patients), and amrinone (19 patients), while diuretic dosages were kept constant." | 3.67 | Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "We evaluated long-term combined vasodilator therapy (hydralazine or ecarazine + isosorbide dinitrate) in 29 patients with chronic congestive heart failure resistant to the optimal conventional therapy." | 3.67 | Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response. ( Hatano, M; Hibiya, K; Ichikawa, M; Nagasawa, M; Ozawa, Y; Saito, S; Tamura, Y; Tomobe, K; Yumikura, S, 1984) |
| "Nine male patients with stable chronic heart failure of different etiology and optimally treated with digoxine and diuretics were given hydralazine, 50 mg b." | 3.67 | Improved cardiac performance during exercise following hydralazine treatment in chronic heart failure. ( Conradson, TB; Rydén, L, 1984) |
| "The central and renal hemodynamic effects of nifedipine were evaluated in nine patients with severe chronic congestive heart failure." | 3.67 | Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure. ( Campese, VM; Elkayam, U; Massry, SG; Rahimtoola, SH; Weber, L, 1984) |
| "The hemodynamic response to a similar reduction of systemic vascular resistance after nifedipine and hydralazine administration was compared in a randomized crossover protocol in patients with severe chronic congestive heart failure (CHF)." | 3.67 | Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure. ( Elkayam, U; McKay, CR; Rahimtoola, SH; Weber, L, 1984) |
| "Recent evidence from the Veterans Administration Vasodilator Heart Failure Trial supports the prophylactic use of a combination of hydralazine and isosorbide dinitrate to prolong life in patients with congestive heart failure." | 3.67 | Can we expect vasodilator therapy to prolong life in patients with congestive heart failure? ( Gottlieb, SS; Kessler, PD; Lee, WH; Packer, M, 1987) |
| "The effect of long-term vasodilator therapy (hydralazine, ecarazine or budralazine + isosorbide dinitrate) were evaluated for 20 patients with chronic congestive heart failure due to dilated cardiomyopathy (DCM) resistant to conventional therapy." | 3.67 | [Long-term vasodilator therapy of chronic refractory heart failure in patients with dilated cardiomyopathy]. ( Hatano, M; Hibiya, K; Kaseda, N; Moriuchi, M; Ozawa, Y; Saito, S; Tamura, Y; Tokutake, E; Tsuji, M; Yumikura, S, 1986) |
| "Changes in circulating catecholamines and transmyocardial catecholamine balance associated with improved left ventricular function were studied in patients with chronic heart failure after treatment with captopril (10 patients) and hydralazine in combination with isosorbide dinitrate (eight patients)." | 3.67 | Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure. ( Burgess, JH; Chatterjee, K; Cousineau, D; Daly, P; Rouleau, JL, 1986) |
| "2 mg propranolol intravenously resulted in acute pulmonary edema." | 3.67 | Severe hypertension, propranolol, and acute pulmonary edema. ( Desai, SP; Fleming, TC; Pierce, EC, 1987) |
| "Dihydralazine, sold under the name of Nepressol, is the derivative of the hydrazinophthalazines used in France for the treatment of severe cardiac failure." | 3.67 | [Role of dihydralazine in the treatment of chronic cardiac insufficiency]. ( Baudouy, M; Camous, JP; Gibelin, P; Leborgne, L; Morand, P, 1985) |
| "The mechanism by which hydralazine improves cardiac function in patients with heart failure is not well characterized." | 3.67 | Effects of hydralazine on pressure-volume and stress-volume relations in congestive heart failure secondary to idiopathic dilated cardiomyopathy. ( Lipscomb, KM; Sanford, CF; Smucker, ML, 1985) |
| "Short-term therapy with oral hydralazine can favorably affect abnormal hemodynamics in patients with congestive heart failure, but the range of dosage is large." | 3.67 | Determinants of systemic availability of oral hydralazine in heart failure. ( Crawford, MH; Kennedy, GT; Ludden, TM, 1985) |
| "The action, efficient dosage and tolerance of a pure vasodilator, dihydralazine, used for the treatment of severe heart failure were studied in 30 children aged 1 month to 14 years." | 3.67 | [Dihydralazine treatment of cardiac insufficiency in children]. ( Fontaine, JL; Girardet, JP; Liechtmaneger, H; Verlhac, S, 1985) |
| " Similarly, chronic congestive heart failure patients, irrespective of the etiology, improve hemodynamically after an infusion of phentolamine, nitroprusside or hydralazine." | 3.66 | Electrophysiologic properties of hydralazine in man. ( Becker, WH; Gould, L; Reddy, CV; Singh, BK; Zen, B, 1980) |
| "The oral angiotensin-converting enzyme inhibitor captopril (CPT) produces beneficial hemodynamic and clinical responses in patients with chronic congestive heart failure (CHF)." | 3.66 | Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost. ( Chatterjee, K; Parmley, WW; Rouleau, JL, 1982) |
| "Simultaneous hemodynamic and radionuclide angiographic assessment was made at rest and during exercise in nine patients with severe chronic congestive heart failure to determine the value of radionuclide left ventricular ejection fraction measurement in predicting the hemodynamic response to short-term treatment with oral hydralazine." | 3.66 | Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response. ( Franklin, BA; Goldberg, MJ; Kerin, NZ; Rubenfire, M; Ruskin, R; Willens, HJ, 1983) |
| "In congestive heart failure, acute administration of the converting enzyme inhibitor captopril leads to a decrease in arterial pressure, systemic vascular resistance, left ventricular filling pressure, and the end-diastolic volumes of both ventricles, as well as to an increase in cardiac index, stroke volume index, right and left ventricular ejection fractions." | 3.66 | Converting-enzyme inhibitor therapy for chronic heart failure. ( Kramer, BL; Massie, BM; Topic, N, 1983) |
| "The hemodynamic benefits and safety of combined therapy with captopril and hydralazine were studied during invasive hemodynamic monitoring in 14 patients with severe heart failure." | 3.66 | Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. ( Combs, DT; Hanlon, JT; Massie, BM; Packer, M, 1983) |
| "We studied the hemodynamic response to orally administered hydralazine (30 mg) and examined the changes in neurohumoral factors in 16 aged patients with chronic congestive heart failure." | 3.66 | Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure. ( Kuwajima, I; Matsushita, S; Murakami, M; Sakai, M; Ueda, K, 1983) |
| "The pharmacodynamics of hydralazine, an arteriolar dilator, were studied in dogs with induced heart failure." | 3.66 | Hydralazine pharmacodynamics in the dog. ( Hamlin, RL; Kittleson, MD, 1983) |
| "The influence of various disease states, other than hypertension, on the pharmacokinetic behaviour of hydralazine is not completely known." | 3.66 | Pharmacokinetics of oral hydralazine in chronic heart failure. ( Hanson, A; Johansson, BW; Wåhlander, LA; Wernersson, B, 1983) |
| "Four studies were conducted in 36 patients with severe chronic heart failure to compare the central hemodynamic effects of captopril (CPT) to other vasodilator agents." | 3.66 | Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs. ( Medina, N; Packer, M; Yushak, M, 1982) |
| " We compared the acute haemodynamic effects of captopril and hydralazine in 11 patients with congestive cardiac failure unresponsive to diuretics and digoxin." | 3.66 | Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction. ( Fitzgerald, DJ; Horgan, J; O'Brien, E; O'Callaghan, WG; O'Malley, K, 1982) |
| "To assess the clinical efficacy of chronic vasodilator therapy for refractory congestive heart failure, the long-term follow-up (mean 13 months, range 3-30 months) was evaluated in 56 patients treated with hydralazine, usually in combination with nitrates." | 3.66 | Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. ( Chatterjee, K; Haughom, F; Massie, B; O'Young, J; Ostland, J; Parmley, W; Ports, T, 1981) |
| "Supine and upright hemodynamic measurements were performed in 10 patients with chronic congestive heart failure, before and during vasodilator therapy with hydralazine and isosorbide dinitrate." | 3.66 | Postural hypotension and tachycardia during hydralazine--isosorbide dinitrate therapy for chronic heart failure. ( Haughom, F; Kramer, B; Massie, B, 1981) |
| "Coronary blood flow and myocardial energetics were assessed after the administration of a parenteral inotrope (dobutamine hydrochloride) and an oral vasodilator agent (hydralazine) in 10 patients with nonischemic congestive heart failure." | 3.66 | Dobutamine and hydralazine: comparative influences of positive inotropy and vasodilation on coronary blood flow and myocardial energetics in nonischemic congestive heart failure. ( Brown, GP; Leier, CV; Magorien, RD; Unverferth, DV, 1983) |
| "To determine whether the circulatory response to hydralazine in heart failure is influenced by initial hemodynamic status or left ventricular (LV) chamber size, 28 patients with chronic LV dysfunction were studied." | 3.66 | Determinants of circulatory response to intravenous hydralazine in congestive heart failure. ( Ferraro, N; Reichek, N; Schwartz, JS; St John Sutton, M; Wilson, JR, 1983) |
| "The acute effects of oral hydralazine, 1 mg/kg, on coronary vascular resistance, coronary blood flow (estimated using the coronary sinus thermodilution technique), and myocardial oxygen consumption were evaluated in 10 patients with chronic (New York Heart Association class III and IV) nonischemic congestive heart failure." | 3.66 | Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure. ( Bambach, D; Boudoulas, H; Brown, GP; Leier, CV; Magorien, RD; Nelson, S; Unverferth, DV, 1982) |
| "Hydralazine reduces pulmonary vascular resistance in patients with primary and secondary pulmonary hypertension, but the effects on right ventricular function of a change in resistance without a reduction in pulmonary arterial pressure are not known." | 3.66 | The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure. ( Handel, F; Peter, RH; Rubin, LJ, 1982) |
| "The effects of dipyridamole, a coronary and peripheral vasodilator drug, on cardiac performance were investigated in nine patients with severe chronic heart failure." | 3.66 | Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine. ( Gorlin, R; Medina, N; Meller, J; Packer, M, 1982) |
| "Eleven dogs with mitral regurgitation and severe cough were given hydralazine for reduction of systemic arterial pressure." | 3.66 | Clinical experience with hydralazine for treatment of otherwise intractable cough in dogs with apparent left-side heart failure. ( Hamlin, RL; Kittleson, MD, 1982) |
| "Several reports have suggested that because isosorbide dinitrate and hydralazine have different and additive haemodynamic effects at rest in patients with chronic heart failure, these agents should be administered in combination." | 3.66 | Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure. ( Haughom, F; Kramer, B; Massie, BM; Shen, E, 1981) |
| "The hemodynamic effects of oral doses of prazosin and hydralazine were studied in the same group of patients with chronic congestive heart failure." | 3.66 | Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure. ( Elkayam, U; Frishman, W; LeJemtel, T; Mathur, M; Sonnenblick, EH; Strom, J, 1981) |
| "Central hemodynamic variables and regional blood flow and vascular resistances were ascertained in patients with severe congestive heart failure before and after the oral administration of prazosin hydrochloride or hydralazine." | 3.66 | Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose. ( Bay, WH; Desch, CE; Leier, CV; Magorien, RD; Triffon, DW; Unverferth, DV, 1981) |
| "The diuretic effect of furosemide was studied in 18 patients with congestive heart failure." | 3.66 | Effect of furosemide in congestive heart failure. ( Akimoto, T; Arita, T; Minami, M; Miyazaki, K; Nomura, A; Yasuda, H, 1981) |
| "The hemodynamic benefits of combined administration of prenalterol (P) with hydralazine (H) were evaluated in ten patients with severe chronic heart failure." | 3.66 | Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure. ( Drexler, H; Just, H; Löllgen, H, 1981) |
| "The long-term effects of vasodilator therapy with oral hydralazine and long-acting nitrates were studied in 34 patients with refractory heart failure." | 3.66 | Results of long-term vasodilator therapy in patients with refractory congestive heart failure. ( Greenberg, BH; Walsh, WF, 1981) |
| "We studied the effect of vasodilator therapy on renal digoxin clearance in patients with chronic congestive heart failure." | 3.66 | Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. ( Benowitz, NL; Carlson, CJ; Cogan, JJ; Humphreys, MH; Rapaport, E, 1981) |
| "Although hydralazine provokes myocardial ischemic events in hypertensive patients not in heart failure by producing reflex tachycardia, the frequency of and mechanisms underlying ischemic events when this drug is administered as a vasodilator agent to patients with heart failure is unknown." | 3.66 | Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy. ( Gorlin, R; Medina, N; Meller, J; Packer, M; Yushak, M, 1981) |
| "The acute effects of nitroprusside infusion and intravenous hydralazine on renal hemodynamics and function were evaluated in nine male patients with severe, low cardiac output, congestive heart failure (CHF)." | 3.66 | Renal effects of nitroprusside and hydralazine in patients with congestive heart failure. ( Carlson, CJ; Cogan, JJ; Humphreys, MH; Rapaport, E, 1980) |
| "Hemodynamic responses to different doses of hydralazine were evaluated in 18 patients with severe refractory resistant heart failure." | 3.66 | Hemodynamic evaluation of hydralazine dosage in refractory heart failure. ( Gorlin, R; Herman, MV; Medina, N; Meller, J; Packer, M, 1980) |
| "To examine the importance of left ventricular chamber size in determing the response to vasodilator therapy, we performed echocardiography in 40 patients with chronic refractory heart failure before they were treated with oral hydralazine." | 3.66 | Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. ( Gorlin, R; Herman, MV; Medina, N; Meller, J; Packer, M, 1980) |
| "Hemodynamic effects of oral hydralazine (200 to 400 mg/d) were evaluated in 11 patients with chronic heart failure after short-term (24 hours) and long-term (average, 8." | 3.66 | Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects. ( Brundage, BH; Chatterjee, K; Holly, AN; Massie, B; Parmley, WW; Ports, TA, 1980) |
| "Nifedipine, a potent coronary vasodilator, was administered in a single sublingual dose of 20 mg to eight patients with mild to moderate congestive heart failure." | 3.66 | Hemodynamic effects of nifedipine in congestive heart failure. ( Ito, T; Ito, Y; Matsumoto, S; Okabe, F; Sada, T; Sato, M; Sekine, I; Su, KM; Takahashi, M; Ueda, A, 1980) |
| " To determine whether this vasodilator elicits a positive inotropic response in the failing human ventricle, hydralazine, 75 or 100 mg, was administered orally to 14 patients with left ventricular dysfunction and congestive heart failure; the results were compared with those of first-dose prazosin at 5 and 10 mg." | 3.66 | Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure. ( Boudoulas, H; Desch, CE; Leier, CV; Lewis, RP; Magorien, RD; Triffon, DW; Unverferth, DV, 1980) |
| "In order to develop a noninvasive means for following left ventricular responses to hydralazine, we measured the systolic time intervals serially in 6 patients with heart failure." | 3.66 | Noninvasive assessment of left ventricular effects of hydralazine in heart failure. ( Deglin, SM; Harris, WS; Jain, AC, 1980) |
| "17 patients with severe chronic heart failure (class III and IV) were prescribed hydralazine, an arterial vasodilatator, orally at doses of 150 mg to 400 mg/day." | 3.66 | [Treatment of severe chronic cardiac insufficiency with dihydralazine. Short-and median-term results]. ( Alison, D; Latour, F; Lavigne, G; Masson, D; Morand, P, 1979) |
| "25 mg/kg hydralazine were studied during cardiac catheterisation of 9 patients with primary congestive cardiomyopathy and heart failure." | 3.66 | [Hemodynamic effects of hydralazine in the cardiac insufficiency of non-obstructive myocardiopathy]. ( Datchary, J; Fernandez, F; Gerbaux, A; Gras, H; Lelguen, C; Pailloncy, M; Ponsonnaille, J, 1979) |
| "It has been shown that hydralazine is beneficial in chronic heart failure by virtue of its afterload reducing effect." | 3.66 | Non-parenteral combined afterload and preload reduction therapy in congestive heart failure. ( Conti, CR; Mehta, J; Pepine, CJ, 1978) |
| "Sudden withdrawal of oral therapy with hydralazine for reduction of afterload in a patient precipitated severe congestive heart failure." | 3.66 | Precipitation of heart failure following sudden withdrawal of hydralazine. ( Black, JR; Mehta, J, 1979) |
| "Of the vasodilators used at present in the treatment of heart failure, only nitroprusside and phentolamine inhibit platelet aggregation at therapeutic dose levels." | 3.66 | Influence of vasodilators used in the therapy of heart failure on platelet aggregation. ( Imhof, P; Pfister, B, 1979) |
| "Changes in left ventricular performance were evaluated in 14 patients with functional New York Heart Association class III or IV chronic heart failure before and after the addition of oral hydralazine to conventional therapy." | 3.66 | Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure. ( Brundage, BH; Chatterjee, K; Gelberg, HJ; Parmley, WW; Ports, TA; Rubin, SA, 1979) |
| " New drugs for the treatment of severe congestive heart failure include dopamine, which has a selective nonadrenergic dilator effect on the renal vascular bed, and dobutamine, which has potent inotropic effects, lowers the left ventricular filling pressure and does not increase the heart rate or the systemic vascular resistance." | 3.66 | Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. ( Armstrong, PW, 1979) |
| "The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure." | 3.66 | Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979) |
| "The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients." | 3.66 | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979) |
| "Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates." | 3.66 | Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy. ( Amsterdam, EA; DeMaria, AN; Laslett, LJ; Mason, DT, 1978) |
| "A patient with severe, chronic congestive heart failure was unresponsive not only to conventional therapy, but also to nonparenteral nitroglycerin and isosorbide dinitrate; he became nitroprusside dependent." | 3.65 | Combination vasodilator therapy for severe chronic congestive heart failure. ( Chatterjee, K; Drew, D; Klausner, SC; Parmley, WW; Polansky, J; Zacherle, B, 1976) |
| "The hemodynamic effects of oral hydralazine were investigated in ten patients (nine in NYHA Class IV and one in Class III) with chronic refractory heart failure." | 3.65 | Oral hydralazine therapy for chronic refractory heart failure. ( Chatterjee, K; Greenberg, B; Klausner, S; Massie, B; Norman, A; Parmley, WW; Werner, J, 1976) |
| "Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge." | 2.82 | Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions? ( Bowlin, B; Finch, C; Hartmann, J; Reedus, J; Richardson, A; Sands, CW; Self, T; Tolley, E, 2016) |
| "Overall mortality or hospitalization for congestive heart failure did not differ between blacks and whites in the placebo group in V-HeFT I." | 2.69 | Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. ( Carson, P; Cohn, JN; Johnson, G; Ziesche, S, 1999) |
| "Congestive heart failure is a clinical syndrome characterized by neuroendocrine activation." | 2.67 | Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Francis, GS; Goldman, S; Johnson, G; Rector, TS; Simon, A, 1993) |
| "Ventricular arrhythmia was a significant independent predictor in V-HeFT II but not in V-HeFT I." | 2.67 | Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. ( Cohn, JN; Fletcher, R; Johnson, GR; Loeb, H; Rector, T; Shabetai, R; Smith, R; Tristani, F, 1993) |
| " Among such questions are: When in the natural history of congestive heart failure should vasodilator therapy be commenced? How effective is long-term administration of vasodilating drugs? May vasodilator therapy decrease mortality in congestive heart failure? What about the efficacy of new vasodilating drugs compared to more traditional ones? In the review of vasodilating drugs besides ACE inhibitors, these questions will be addressed." | 2.66 | Aspects on "traditional" vasodilators in the treatment of chronic heart failure. ( Conradson, TB; Rydén, L, 1986) |
| "Treatment with hydralazine-nitrate produced a 28% reduction in mortality compared with that in patients receiving placebo (95% confidence interval, 3% to 46%), whereas prazosin exerted no apparent beneficial effect." | 2.66 | Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. ( Archibald, DG; Cohn, JN; Dunkman, WB; Flohr, KH; Franciosa, JA; Francis, GS; Harston, WE; Jacobs, W; Tristani, FE; Ziesche, S, 1987) |
| "Heart failure affects more than 6 million people in the United States and incurs a heavy toll in morbidity, mortality, and health care costs." | 2.58 | Heart Failure. ( Wu, A, 2018) |
| "Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities." | 2.53 | An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF). ( Adhyaru, B; Raj, L, 2016) |
| "Heart failure is a costly and difficult disease to treat." | 2.50 | Adjunctive therapy and management of the transition of care in patients with heart failure. ( Eisen, HJ; Feitell, S; Hankins, SR, 2014) |
| "Heart failure affects 5 million Americans, and nearly 50% of these are women." | 2.45 | Heart failure in women: a need for prospective data. ( Hsich, EM; Piña, IL, 2009) |
| " To select the most appropriate drug therapy for patients with heart failure, clinicians should consider results from clinical trials in specific patient populations, adverse-event profiles, tolerability, cost, and dosing regimens." | 2.44 | Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers. ( Norgard, NB; Stark, JE, 2008) |
| "Heart failure is a substantial cause of increased morbidity and mortality in the African-American population, with poorer prognosis versus white patients." | 2.41 | Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con position. ( Ferdinand, DP; Ferdinand, KC; Serrano, CC, 2002) |
| "Systolic heart failure is the most common cause of CHF presentations." | 2.41 | Clinical treatment regimens for chronic heart failure: a review. ( Gould, PA; Kaye, DM, 2002) |
| "Chronic heart failure is a complex syndrome: as such it may perhaps be too simplistic to expect any single parameter to be universally predictive of drug effects on mortality, especially when each drug works by different mechanisms." | 2.40 | Can drug effects on mortality in heart failure be predicted by any surrogate measure? ( Struthers, AD; Yee, KM, 1997) |
| "Heart failure is a physiopathological condition, with an increasing incidence and prevalence, involving the action of a series of mechanisms known as 'compensators', which are phylogenetically ready to normalize minute volume and blood pressure." | 2.39 | [Neurohormonal factors in heart failure. I]. ( Cosín Aguilar, J; Cruz Fernández, JM; de Teresa Galván, E; Ferreira Montero, IJ; López-Sendón, J; Soler Soler, J; Tamargo Menéndez, J, 1996) |
| "Heart failure is common in the elderly and is associated with a significant morbidity and mortality." | 2.39 | Diagnosis and management of heart failure in the elderly. ( King, D, 1996) |
| "The reduction in mortality from cardiac failure was demonstrated in the Veterans I Study in association with Hydralazine compared to conventional digitalo-diuretic therapy but seems less important than that obtained by angiotensin converting enzyme inhibitors." | 2.38 | [Nitrate derivatives and cardiac insufficiency]. ( Isnard, R; Komajda, M; Lechat, P, 1992) |
| "Many studies of congestive heart failure are done without explicit diagnostic criteria." | 2.37 | Diagnostic heterogeneity in clinical trials for congestive heart failure. ( Alderman, MH; Marantz, PR; Tobin, JN, 1988) |
| "Reduced mortality rates in congestive heart failure with vasodilator therapy has not been demonstrated, and prediction of clinical response to therapy is difficult." | 2.37 | Vasodilator therapy. ( Sutton, FJ, 1986) |
| "Congestive heart failure is accompanied by a number of compensatory mechanisms that may overshoot the mark." | 2.37 | Role of isosorbide dinitrate in management of chronic congestive heart failure. ( Parmley, WW, 1985) |
| " However, there are both clinical data and theoretic reasons to anticipate that some degree of tolerance may develop during the long-term use of most agents." | 2.36 | Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure. ( Alexander, RW; Braunwald, E; Colucci, WS; Williams, GH, 1981) |
| "Hydralazine is a smooth muscle relaxant and a potent arteriolar dilator." | 2.36 | Hydralazine in heart failure. ( Chatterjee, K, 1983) |
| "Treatment with sodium nitrite and hydralazine restored NO bioavailability, reduced oxidative and nitrosative stress, preserved endothelial function and mitochondrial respiration, limited the fibrotic response, and improved exercise capacity, ultimately attenuating the severity of "two-hit" HFpEF." | 1.91 | Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a "2-Hit" Murine Model. ( Doiron, JE; Goodchild, TT; Koul, K; LaPenna, KB; Lefer, DJ; Li, Z; Moles, K; Patel, RB; Polhemus, DJ; Shah, SJ; Sharp, TE; Wang, JS; Xia, H, 2023) |
| "Captopril patients were matched 1:2 to H-ISDN patients, based on serum creatinine and race (Black vs non-Black)." | 1.62 | Captopril Versus Hydralazine-Isosorbide Dinitrate Vasodilator Protocols in Patients With Acute Decompensated Heart Failure Transitioning From Sodium Nitroprusside. ( Amar, M; Faulkenberg, K; Lam, SW; Perez, A; Tang, WHW; Williams, JB, 2021) |
| "Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate (GMP) pathway." | 1.62 | Vericiguat, organic nitrates, and heart failure in African Americans. ( Guglin, M; Ilonze, OJ, 2021) |
| "Heart failure is an established predictor of primary cardiac events during pregnancy." | 1.40 | Treatment of pre-existing cardiomyopathy during pregnancy. ( Ascoop, AK; De Backer, J; De Pauw, M; Gevaert, S; Roelens, K; Tromp, F, 2014) |
| " Experimental data suggests that hydralazine, given concomitantly, attenuates the development of hemodynamic tolerance to ISDN and may increase bioavailability of NO in the vasculature." | 1.35 | Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. ( Jacob, RG; Thadani, U, 2008) |
| "Food and Drug Administration (FDA) for treating heart failure in black patients." | 1.34 | BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval. ( Bibbins-Domingo, K; Fernandez, A, 2007) |
| "Systolic heart failure is a condition that exerts a devastating toll on those affected." | 1.34 | Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure. ( Flack, JM, 2007) |
| "Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of this compound." | 1.33 | Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. ( Bachschmid, M; Coldewey, M; Daiber, A; Huth, C; Kaiser, K; Mülsch, A; Münzel, T; Nazirisadeh, Y; Oelze, M; Schildknecht, S; Tsilimingas, N; Ullrich, V, 2005) |
| "Furosemide was added after the 3-week examination, and at 6 months, dogs had received furosemide for at least 4 months." | 1.29 | Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. ( Häggström, J; Hansson, K; Karlberg, BE; Kvart, C; Madej, A; Olsson, K, 1996) |
| "In patients with congestive heart failure (CHF), overactivity of the sympathetic nervous system may be accompanied by an impairment of the baroreflex control mechanism." | 1.28 | Baroreceptor-mediated release of vasopressin in patients with chronic congestive heart failure and defective sympathetic responsiveness. ( Dietz, R; Kübler, W; Leinberger, H; Manthey, J; Opherk, D; Osterziel, KJ, 1992) |
| "Atrial volumes and mitral and tricuspid regurgitation, in addition to left ventricular ejection fraction and indexes of left ventricular contractility (mean acceleration, ejection time and peak systolic pressure/end-systolic volume index), were measured using 2-dimensional and Doppler echocardiography and color flow imaging in 30 patients with advanced CHF, before and after acute vasodilator and diuretic therapy tailored to hemodynamic goals." | 1.28 | Acute reduction of atrial overload during vasodilator and diuretic therapy in advanced congestive heart failure. ( Child, JS; Hamilton, MA; Moriguchi, JD; Stevenson, LW; Woo, M, 1990) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 1.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "Even though cardiac hypertrophy is viewed as a beneficial compensatory process that normalizes wall stress, the increased muscle mass carries with it the need of increased blood supply." | 1.27 | Effects of vasodilators on the coronary circulation in congestive heart failure. ( Burkart, F; Kiowski, W, 1988) |
| "Each infant had congestive heart failure and angiographic evidence of markedly depressed left ventricular ejection fraction (0." | 1.27 | Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure. ( Appleton, S; Artman, M; Boucek, RJ; Graham, TP; Parrish, MD, 1987) |
| "Prehydralazine baseline data were therefore compared with values 35 minutes after hydralazine." | 1.26 | Hemodynamic effects of hydralazine in infants with a large ventricular septal defect. ( Beekman, RH; Rocchini, AP; Rosenthal, A, 1982) |
| "With hydralazine there were parallel changes in the rate-pressure product and MVO2." | 1.26 | Vasodilators in heart failure secondary to coronary artery disease. ( Chatterjee, K; Parmley, WW; Rouleau, JL, 1982) |
| "Hydralazine did not increase arterial oxygen tension (0." | 1.26 | Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment. ( Brown, HV; Rubin, SA; Swan, HJ, 1982) |
| " Lesser problems include the construction of effective dosage schedules, deleterious effects after sudden withdrawal, development of tolerance, and side effects." | 1.26 | The longer term efficacy of vasodilators in heart failure. ( Hernandez, J; Owens, CW, 1982) |
| "Hydralazine was administered in a single oral dose of 50 to 100 mg in 16 patients with left ventricular failure due to cardiomyopathy." | 1.26 | Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. ( Cohn, JN; Franciosa, JA; Pierpont, G, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 255 (51.00) | 18.7374 |
| 1990's | 60 (12.00) | 18.2507 |
| 2000's | 125 (25.00) | 29.6817 |
| 2010's | 49 (9.80) | 24.3611 |
| 2020's | 11 (2.20) | 2.80 |
| Authors | Studies |
|---|---|
| Sandhu, AT | 1 |
| Kohsaka, S | 1 |
| Turakhia, MP | 1 |
| Lewis, EF | 1 |
| Heidenreich, PA | 3 |
| Callier, SL | 1 |
| Payne, PW | 1 |
| Akinniyi, D | 1 |
| McPartland, K | 1 |
| Richardson, TL | 1 |
| Rothstein, MA | 1 |
| Royal, CDM | 1 |
| Shahzad Qamar, A | 1 |
| Zamir, A | 1 |
| Khalid, S | 1 |
| Ashraf, W | 1 |
| Imran, I | 1 |
| Hussain, I | 1 |
| Rehman, AU | 1 |
| Saeed, H | 1 |
| Majeed, A | 1 |
| Alqahtani, F | 1 |
| Rasool, MF | 1 |
| Warner, AL | 1 |
| Lu, L | 1 |
| Ghaznavi, Z | 1 |
| Jackevicius, CA | 1 |
| Ahmad, FS | 1 |
| Ahmad, T | 1 |
| Allen, LA | 1 |
| LaPenna, KB | 1 |
| Li, Z | 1 |
| Doiron, JE | 1 |
| Sharp, TE | 1 |
| Xia, H | 1 |
| Moles, K | 1 |
| Koul, K | 1 |
| Wang, JS | 1 |
| Polhemus, DJ | 1 |
| Goodchild, TT | 1 |
| Patel, RB | 1 |
| Shah, SJ | 1 |
| Lefer, DJ | 1 |
| Giblin, EM | 1 |
| Adams, KF | 3 |
| Hill, L | 1 |
| Fonarow, GC | 8 |
| Williams, FB | 1 |
| Sharma, PP | 1 |
| Albert, NM | 1 |
| Butler, J | 8 |
| DeVore, AD | 1 |
| Duffy, CI | 1 |
| Hernandez, AF | 3 |
| McCague, K | 1 |
| Spertus, JA | 1 |
| Thomas, L | 1 |
| Patterson, JH | 2 |
| Doughem, K | 1 |
| Battisha, A | 1 |
| Sheikh, O | 1 |
| Konduru, L | 1 |
| Madoukh, B | 1 |
| Al-Sadawi, M | 1 |
| Shaikh, S | 1 |
| Wiggers, H | 1 |
| Køber, L | 1 |
| Gislason, G | 1 |
| Schou, M | 1 |
| Poulsen, MK | 1 |
| Vraa, S | 1 |
| Nielsen, OW | 1 |
| Bruun, NE | 1 |
| Nørrelund, H | 1 |
| Hollingdal, M | 1 |
| Barasa, A | 1 |
| Bøttcher, M | 1 |
| Dodt, K | 1 |
| Hansen, VB | 1 |
| Nielsen, G | 1 |
| Knudsen, AS | 1 |
| Lomholdt, J | 1 |
| Mikkelsen, KV | 1 |
| Jonczy, B | 1 |
| Brønnum-Schou, J | 1 |
| Poenaru, MP | 1 |
| Abdulla, J | 1 |
| Raymond, I | 1 |
| Mahboubi, K | 1 |
| Sillesen, K | 1 |
| Serup-Hansen, K | 1 |
| Madsen, JS | 1 |
| Kristensen, SL | 1 |
| Larsen, AH | 1 |
| Bøtker, HE | 1 |
| Torp-Petersen, C | 1 |
| Eiskjær, H | 1 |
| Møller, J | 1 |
| Hassager, C | 1 |
| Steffensen, FH | 1 |
| Bibby, BM | 1 |
| Refsgaard, J | 1 |
| Høfsten, DE | 1 |
| Mellemkjær, S | 1 |
| Gustafsson, F | 1 |
| Amar, M | 1 |
| Lam, SW | 1 |
| Faulkenberg, K | 1 |
| Perez, A | 1 |
| Tang, WHW | 1 |
| Williams, JB | 1 |
| Ilonze, OJ | 1 |
| Guglin, M | 1 |
| Xu, W | 1 |
| Qian, L | 1 |
| Yuan, X | 1 |
| Lu, Y | 1 |
| Papadimitriou, L | 1 |
| Hamo, CE | 1 |
| Ofili, E | 5 |
| Anand, I | 2 |
| Williams, RA | 1 |
| Akinboboye, O | 1 |
| Xu, L | 1 |
| Puckrein, G | 3 |
| Ziaeian, B | 1 |
| Cohn, JN | 53 |
| Chang, KW | 1 |
| Beri, N | 1 |
| Nguyen, NH | 1 |
| Arbit, B | 1 |
| Fox, S | 1 |
| Mojaver, S | 1 |
| Clopton, P | 1 |
| Tam, SW | 11 |
| Taylor, AL | 17 |
| Maisel, AS | 1 |
| Anand, IS | 4 |
| Nyolczas, N | 1 |
| Dékány, M | 1 |
| Muk, B | 1 |
| Szabó, B | 1 |
| Kayibanda, JF | 1 |
| Girouard, C | 1 |
| Grégoire, JP | 1 |
| Demers, E | 1 |
| Moisan, J | 1 |
| Wu, A | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| Brewster, LM | 1 |
| Al-Mohammad, A | 1 |
| Lim, WY | 1 |
| Woldman, S | 1 |
| Sweitzer, NK | 1 |
| Hetzel, SJ | 1 |
| Skalski, J | 1 |
| Velez, M | 1 |
| Eggleston, K | 1 |
| Mitchell, GF | 1 |
| Golwala, HB | 1 |
| Thadani, U | 2 |
| Liang, L | 2 |
| Stavrakis, S | 1 |
| Yancy, CW | 11 |
| Bhatt, DL | 2 |
| Feitell, S | 1 |
| Hankins, SR | 1 |
| Eisen, HJ | 1 |
| Gupta, D | 2 |
| Georgiopoulou, VV | 2 |
| Kalogeropoulos, AP | 2 |
| Marti, CN | 1 |
| Gheorghiade, M | 4 |
| Konstam, MA | 3 |
| Gevaert, S | 1 |
| De Pauw, M | 1 |
| Tromp, F | 1 |
| Ascoop, AK | 1 |
| Roelens, K | 1 |
| De Backer, J | 1 |
| Sharma, A | 1 |
| Colvin-Adams, M | 2 |
| Ferdinand, KC | 6 |
| Elkayam, U | 9 |
| Mancini, D | 1 |
| Piña, I | 1 |
| Feldman, AM | 3 |
| McNamara, D | 1 |
| Leggett, C | 1 |
| Win, S | 1 |
| Rector, TS | 5 |
| Oliveira-Paula, GH | 1 |
| Cole, RT | 2 |
| Bristow, MR | 1 |
| McNamara, DM | 2 |
| Worcel, M | 14 |
| Hanley-Yanez, K | 1 |
| Farag, M | 1 |
| Mabote, T | 1 |
| Shoaib, A | 1 |
| Zhang, J | 1 |
| Nabhan, AF | 1 |
| Clark, AL | 1 |
| Cleland, JG | 1 |
| Khazanie, P | 1 |
| Curtis, LH | 1 |
| Eapen, ZJ | 1 |
| Peterson, ED | 1 |
| Naegele, M | 1 |
| Flammer, AJ | 1 |
| Enseleit, F | 1 |
| Ruschitzka, F | 1 |
| Yee, J | 1 |
| Sliwa, K | 1 |
| Damasceno, A | 1 |
| Davison, BA | 1 |
| Mayosi, BM | 1 |
| Sani, MU | 1 |
| Ogah, O | 1 |
| Mondo, C | 1 |
| Ojji, D | 1 |
| Dzudie, A | 1 |
| Kouam, CK | 1 |
| Yonga, G | 1 |
| Ba, SA | 1 |
| Ogola, E | 1 |
| Edwards, C | 1 |
| Milo, O | 1 |
| Cotter, G | 1 |
| Richardson, A | 1 |
| Tolley, E | 1 |
| Hartmann, J | 1 |
| Reedus, J | 1 |
| Bowlin, B | 1 |
| Finch, C | 1 |
| Sands, CW | 1 |
| Self, T | 1 |
| Raj, L | 1 |
| Adhyaru, B | 1 |
| Stewart, GC | 1 |
| Kittleson, MM | 1 |
| Patel, PC | 1 |
| Cowger, JA | 1 |
| Patel, CB | 1 |
| Mountis, MM | 1 |
| Johnson, FL | 1 |
| Guglin, ME | 1 |
| Rame, JE | 1 |
| Teuteberg, JJ | 1 |
| Stevenson, LW | 5 |
| Zamani, P | 1 |
| Akers, S | 1 |
| Soto-Calderon, H | 1 |
| Beraun, M | 1 |
| Koppula, MR | 1 |
| Varakantam, S | 1 |
| Rawat, D | 1 |
| Shiva-Kumar, P | 1 |
| Haines, PG | 1 |
| Chittams, J | 1 |
| Townsend, RR | 1 |
| Witschey, WR | 1 |
| Segers, P | 1 |
| Chirinos, JA | 1 |
| Norgard, NB | 1 |
| Stark, JE | 1 |
| Dorr, GM | 1 |
| Jones, DS | 1 |
| Ellison, GT | 2 |
| Kaufman, JS | 1 |
| Head, RF | 1 |
| Martin, PA | 2 |
| Kahn, JD | 3 |
| Tutton, R | 2 |
| Smart, A | 1 |
| Ashcroft, R | 1 |
| Caulfield, T | 1 |
| Harry, S | 1 |
| Reverby, SM | 1 |
| Münzel, T | 5 |
| Ghali, JK | 6 |
| Sabolinski, ML | 9 |
| Lindenfeld, J | 2 |
| Schrock, JW | 1 |
| Emerman, CL | 1 |
| Yu, JH | 1 |
| Goering, S | 1 |
| Fullerton, SM | 1 |
| Holm, S | 1 |
| Jacob, RG | 1 |
| Tobelmann, P | 1 |
| Janosko, K | 1 |
| Venkitachalam, L | 1 |
| Yancy, C | 4 |
| Mullens, W | 1 |
| Abrahams, Z | 1 |
| Francis, GS | 6 |
| Sokos, G | 1 |
| Starling, RC | 2 |
| Young, JB | 2 |
| Taylor, DO | 1 |
| Tang, WH | 1 |
| Coons, SJ | 1 |
| Hammermeister, KE | 1 |
| Fairclough, D | 1 |
| Emsermann, CB | 1 |
| Hamman, R | 1 |
| Ho, M | 1 |
| Phibbs, S | 1 |
| Plomondon, M | 1 |
| Valuck, R | 1 |
| West, D | 1 |
| Steiner, JF | 1 |
| Wilson, RM | 1 |
| De Silva, DS | 1 |
| Sato, K | 1 |
| Izumiya, Y | 1 |
| Sam, F | 1 |
| Hsich, EM | 1 |
| Piña, IL | 1 |
| Gori, T | 1 |
| Ishizawar, D | 1 |
| Frank, D | 1 |
| Gallagher, TH | 1 |
| Sellers, SL | 1 |
| Cooper, LA | 1 |
| Price, EG | 1 |
| Odunlami, AO | 1 |
| Bonham, VL | 1 |
| Kopecky, SL | 1 |
| Litin, SC | 1 |
| Feldman, A | 1 |
| Chirkov, YY | 1 |
| De Sciscio, M | 1 |
| Sverdlov, AL | 1 |
| Leslie, S | 1 |
| Sage, PR | 1 |
| Horowitz, JD | 1 |
| Rusert, BM | 1 |
| Royal, CD | 1 |
| Quyyumi, A | 1 |
| Mitchell, JE | 1 |
| Trivedi, K | 1 |
| O'Neal, W | 1 |
| Jacoby, D | 1 |
| Albajrami, O | 1 |
| Bellumkonda, L | 1 |
| Hare, JM | 2 |
| Mann, DL | 1 |
| Valchanov, KP | 1 |
| Arrowsmith, JE | 1 |
| Ziesche, S | 9 |
| Archambault, WT | 3 |
| Westermann, D | 1 |
| Becher, PM | 1 |
| Lindner, D | 1 |
| Savvatis, K | 1 |
| Xia, Y | 1 |
| Fröhlich, M | 1 |
| Hoffmann, S | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Serrano, CC | 1 |
| Ferdinand, DP | 1 |
| Franciosa, JA | 18 |
| Olukotun, A | 1 |
| Ferdinand, K | 3 |
| Loscalzo, J | 1 |
| Gould, PA | 1 |
| Kaye, DM | 1 |
| Ahmed, A | 1 |
| Anker, SD | 1 |
| Negassa, A | 1 |
| Coats, AJ | 1 |
| Afzal, R | 1 |
| Poole-Wilson, PA | 1 |
| Yusuf, S | 1 |
| Klein, L | 1 |
| O'Connor, CM | 1 |
| Gattis, WA | 1 |
| Zampino, M | 1 |
| de Luca, L | 2 |
| Vitarelli, A | 1 |
| Fedele, F | 1 |
| MEIER, R | 1 |
| BRUNI, C | 1 |
| TRIPOD, J | 1 |
| JAMES, JA | 1 |
| FINK, CW | 1 |
| WEAVER, KH | 1 |
| Levine, TB | 4 |
| Levine, AB | 1 |
| Bolenbaugh, J | 1 |
| Green, PR | 1 |
| Kahn, J | 5 |
| Chatterjee, K | 20 |
| Carson, P | 6 |
| D'Agostino, R | 1 |
| Taylor, M | 2 |
| Adams, K | 2 |
| Sabolinski, M | 1 |
| Bloche, MG | 2 |
| Petsko, GA | 1 |
| Brandt, D | 1 |
| Payne, JW | 1 |
| Massie, BM | 8 |
| Crivellari, M | 1 |
| Bove, T | 1 |
| Landoni, G | 1 |
| Zangrillo, A | 1 |
| Moran, AE | 1 |
| Cooper, RS | 1 |
| Eisenberger, AB | 1 |
| Bellin, EY | 1 |
| Chow, AY | 1 |
| Peota, C | 1 |
| Saul, S | 4 |
| Wadman, M | 1 |
| Aronow, WS | 2 |
| Czap, A | 1 |
| Wallace, TW | 1 |
| Drazner, MH | 1 |
| Ibrahim, OA | 1 |
| Dunlap, ME | 1 |
| Branca, MA | 1 |
| Thompson, CA | 1 |
| Senior, K | 1 |
| Nissen, SE | 1 |
| Bowser, R | 1 |
| Fiscella, K | 1 |
| Bitar, F | 1 |
| Daiber, A | 1 |
| Oelze, M | 1 |
| Coldewey, M | 1 |
| Kaiser, K | 1 |
| Huth, C | 1 |
| Schildknecht, S | 1 |
| Bachschmid, M | 1 |
| Nazirisadeh, Y | 1 |
| Ullrich, V | 1 |
| Mülsch, A | 1 |
| Tsilimingas, N | 1 |
| Angus, DC | 1 |
| Linde-Zwirble, WT | 1 |
| Villagra, VG | 1 |
| Winkelmayer, WC | 1 |
| Laustsen, G | 1 |
| Gilbert, M | 1 |
| Wimett, L | 1 |
| Singh, S | 1 |
| Finks, SW | 1 |
| Finks, AL | 1 |
| Self, TH | 1 |
| Vivian, EM | 1 |
| Hoffman, S | 1 |
| Ruel, MD | 1 |
| Haga, SB | 1 |
| Ginsburg, GS | 1 |
| Aguiar-Souto, P | 1 |
| Garcia-Pavia, P | 1 |
| Silva-Melchor, L | 1 |
| Ortigosa, FJ | 1 |
| Cheng, JW | 1 |
| Liang, Q | 1 |
| Elson, AC | 1 |
| Gerdes, AM | 1 |
| Crouch, MA | 1 |
| Adorisio, R | 1 |
| Rossi, J | 1 |
| Bibbins-Domingo, K | 2 |
| Fernandez, A | 2 |
| Temple, R | 1 |
| Stockbridge, NL | 1 |
| Olukotun, AY | 2 |
| Flack, JM | 1 |
| Duster, T | 1 |
| Echols, MR | 1 |
| Hoover, EL | 1 |
| Sade, RM | 1 |
| Matthews, GE | 1 |
| Crawley, L | 1 |
| Braman, VM | 1 |
| Rosen, D | 1 |
| Decaro, MV | 1 |
| Graham, MG | 1 |
| Curry, CL | 1 |
| Séguin, B | 1 |
| Hardy, B | 1 |
| Singer, PA | 1 |
| Daar, AS | 1 |
| Huggett, B | 1 |
| Finnerty, FA | 2 |
| Davidov, M | 1 |
| Kakaviatos, N | 1 |
| Opie, LH | 1 |
| Weber, KT | 3 |
| Andrews, V | 1 |
| Kinasewitz, GT | 2 |
| Janicki, JS | 2 |
| Fishman, AP | 1 |
| Fischer, E | 1 |
| Siegenthaler, W | 1 |
| Drexler, H | 2 |
| Löllgen, H | 2 |
| Just, H | 2 |
| Leinberger, H | 2 |
| Mäurer, W | 1 |
| Haueisen, H | 1 |
| Schuler, G | 1 |
| Kübler, W | 3 |
| Markham, RV | 1 |
| Gilmore, A | 1 |
| Pettinger, WA | 1 |
| Brater, DC | 1 |
| Corbett, JR | 1 |
| Firth, BG | 1 |
| Shevchenko, VA | 1 |
| Nelson, GI | 2 |
| Silke, B | 2 |
| Ahuja, RC | 1 |
| Walker, C | 1 |
| Forsyth, DR | 2 |
| Verma, SP | 2 |
| Taylor, SH | 4 |
| Mathey, DG | 1 |
| Bleifeld, W | 2 |
| Prichard, BN | 1 |
| Gould, L | 3 |
| Reddy, CV | 2 |
| Zen, B | 1 |
| Singh, BK | 1 |
| Becker, WH | 1 |
| Ochs, HR | 1 |
| Bodem, G | 1 |
| Colucci, WS | 1 |
| Williams, GH | 1 |
| Alexander, RW | 1 |
| Braunwald, E | 1 |
| Curós, A | 1 |
| Gausí, C | 1 |
| Perea, MA | 1 |
| Martín-Comín, J | 1 |
| Ramos, M | 1 |
| Artese, D | 1 |
| Albani, A | 1 |
| Di Tomasso, E | 1 |
| Bing, OH | 1 |
| Sen, S | 1 |
| Conrad, CH | 1 |
| Brooks, WW | 1 |
| Mason, DT | 6 |
| Awan, NA | 2 |
| Joye, JA | 1 |
| Lee, G | 1 |
| DeMaria, AN | 2 |
| Amsterdam, EA | 3 |
| Rouleau, JL | 5 |
| Parmley, WW | 12 |
| Goldberg, MJ | 1 |
| Franklin, BA | 1 |
| Rubenfire, M | 1 |
| Kerin, NZ | 1 |
| Willens, HJ | 1 |
| Ruskin, R | 1 |
| Packer, M | 13 |
| Medina, N | 9 |
| Yushak, M | 5 |
| Romankiewicz, N | 1 |
| Artman, M | 4 |
| Parrish, MD | 3 |
| Graham, TP | 4 |
| Kramer, BL | 1 |
| Topic, N | 1 |
| Hanlon, JT | 1 |
| Combs, DT | 1 |
| Schwartz, AB | 1 |
| Larbig, D | 1 |
| Nasse, H | 1 |
| Feldman, R | 1 |
| Beekman, RH | 2 |
| Rocchini, AP | 2 |
| Dick, M | 1 |
| Crowley, DC | 1 |
| Rosenthal, A | 2 |
| Ueda, K | 1 |
| Sakai, M | 1 |
| Matsushita, S | 1 |
| Kuwajima, I | 1 |
| Murakami, M | 1 |
| Conradson, TB | 6 |
| Rydén, L | 5 |
| Ahlmark, G | 1 |
| Saetre, H | 1 |
| Persson, S | 1 |
| Nyquist, O | 1 |
| Wernersson, B | 2 |
| Satinsky, JD | 1 |
| Pouleur, H | 2 |
| Engler, RL | 1 |
| Link, J | 2 |
| Printz, MP | 1 |
| Covell, JW | 2 |
| Ciafone, RA | 1 |
| Gopalaswamy, C | 1 |
| Bertel, O | 1 |
| Saito, S | 2 |
| Ichikawa, M | 1 |
| Ozawa, Y | 2 |
| Yumikura, S | 2 |
| Nagasawa, M | 1 |
| Hibiya, K | 2 |
| Tamura, Y | 2 |
| Tomobe, K | 1 |
| Hatano, M | 2 |
| Magorien, RD | 7 |
| Unverferth, DV | 6 |
| Leier, CV | 8 |
| Timmis, AD | 1 |
| Richardson, PJ | 1 |
| Bolte, HD | 1 |
| Reifart, N | 2 |
| Kaltenbach, M | 2 |
| Bussmann, WD | 2 |
| Weber, L | 3 |
| Campese, VM | 1 |
| Massry, SG | 1 |
| Rahimtoola, SH | 4 |
| Kittleson, MD | 3 |
| Hamlin, RL | 2 |
| Hussain, M | 1 |
| Hanson, A | 1 |
| Johansson, BW | 1 |
| Wåhlander, LA | 1 |
| Kothiala, A | 1 |
| Ramnani, K | 1 |
| Patel, HR | 2 |
| Mehta, NC | 2 |
| Shah, CP | 2 |
| Mehegan, JP | 1 |
| Unverferth, BJ | 1 |
| Boerth, RC | 1 |
| Boucek, RJ | 2 |
| McKay, CR | 1 |
| Greenberg, BH | 5 |
| Ke, YN | 2 |
| Fitzgerald, DJ | 1 |
| O'Callaghan, WG | 1 |
| O'Malley, K | 1 |
| Horgan, J | 1 |
| O'Brien, E | 1 |
| Massie, B | 6 |
| Ports, T | 1 |
| Parmley, W | 2 |
| Ostland, J | 1 |
| O'Young, J | 1 |
| Haughom, F | 4 |
| Kramer, B | 3 |
| Khomenko, VL | 2 |
| Pomerantsev, VP | 1 |
| Vasiuk, IuA | 1 |
| Pierpont, G | 3 |
| Meller, J | 8 |
| Wagner, GC | 1 |
| Robinson, PH | 1 |
| Haq, A | 1 |
| Rakowski, H | 1 |
| Baigrie, R | 1 |
| McLaughlin, P | 1 |
| Burns, R | 1 |
| Tihal, H | 1 |
| Hilton, D | 1 |
| Feiglin, D | 1 |
| Mandell, HN | 1 |
| Deglin, SM | 2 |
| Bunge, T | 1 |
| Brown, GP | 2 |
| Rutishauser, W | 1 |
| Wilson, JR | 4 |
| Martin, JL | 1 |
| Ferraro, N | 3 |
| Hamilton, RA | 1 |
| St John Sutton, M | 1 |
| Schwartz, JS | 1 |
| Reichek, N | 1 |
| Fried, R | 1 |
| Steinherz, LJ | 1 |
| Levin, AR | 1 |
| Linday, L | 1 |
| Tan, CT | 1 |
| Miller, D | 1 |
| Freis, E | 1 |
| LeJemtel, TH | 2 |
| Ribner, HS | 2 |
| Hellman, C | 1 |
| Strom, J | 3 |
| Frishman, W | 2 |
| Strobeck, J | 1 |
| Sonnenblick, EH | 3 |
| Benge, W | 1 |
| Hiramatsu, B | 1 |
| Serbin, VI | 1 |
| Gasanova, AS | 1 |
| Engler, R | 1 |
| Printz, M | 1 |
| West, J | 1 |
| Henis, MM | 1 |
| Gorlin, R | 6 |
| Nelson, S | 1 |
| Boudoulas, H | 2 |
| Bambach, D | 1 |
| Patel, S | 1 |
| Gomes, GI | 1 |
| Rubin, LJ | 1 |
| Handel, F | 1 |
| Peter, RH | 1 |
| Rubin, SA | 5 |
| Brown, HV | 1 |
| Swan, HJ | 2 |
| Bussey, HI | 1 |
| Nomura, A | 3 |
| Yasuda, H | 2 |
| Katoh, K | 1 |
| Akimoto, T | 2 |
| Miyazaki, K | 2 |
| Arita, T | 2 |
| Kolibash, AJ | 1 |
| Robinson, JL | 1 |
| Siemienczuk, D | 2 |
| Nathan, MD | 1 |
| Prause, J | 1 |
| Hernandez, J | 1 |
| Owens, CW | 1 |
| Marin-Neto, JA | 1 |
| Secches, AL | 1 |
| Maciel, BC | 1 |
| Gallo Júnior, L | 1 |
| Terra-Filho, J | 1 |
| Manço, JC | 1 |
| Amorin, DS | 1 |
| Lanas, F | 2 |
| Salvatici, R | 2 |
| Opazo, JA | 2 |
| Stockins, B | 1 |
| Saavedra, J | 2 |
| Schulthess, L | 1 |
| Shen, E | 1 |
| Mathur, M | 1 |
| LeJemtel, T | 1 |
| Triffon, DW | 2 |
| Desch, CE | 2 |
| Bay, WH | 1 |
| Minami, M | 1 |
| Walsh, WF | 1 |
| Cogan, JJ | 2 |
| Humphreys, MH | 2 |
| Carlson, CJ | 2 |
| Benowitz, NL | 1 |
| Rapaport, E | 2 |
| Mathey, D | 3 |
| Hanrath, P | 1 |
| Polster, J | 1 |
| Witte, G | 1 |
| Montz, R | 1 |
| Untereker, W | 1 |
| Hirshfeld, J | 1 |
| Gronda, E | 1 |
| Mafrici, A | 1 |
| Ferrari, D | 1 |
| Cataldo, G | 1 |
| Salvadè, P | 1 |
| Pirelli, S | 1 |
| Mauri, F | 1 |
| Faletra, F | 1 |
| Carù, B | 1 |
| Clark, AJ | 1 |
| McMichael, HB | 1 |
| Heer, KR | 1 |
| Davies, J | 1 |
| MacArthur, CG | 1 |
| McGuinness, JB | 1 |
| Ballantyne, D | 1 |
| Baxter, RH | 1 |
| Clark, RS | 1 |
| Weir, JI | 1 |
| Pierpont, GL | 2 |
| Brown, DC | 1 |
| Atkins, FL | 1 |
| Segal, BL | 1 |
| Hale, KA | 1 |
| Herman, MV | 3 |
| Cabaniss, CD | 1 |
| Ports, TA | 5 |
| Brundage, BH | 4 |
| Holly, AN | 1 |
| Matsumoto, S | 1 |
| Ito, T | 1 |
| Sada, T | 1 |
| Takahashi, M | 1 |
| Su, KM | 1 |
| Ueda, A | 1 |
| Okabe, F | 1 |
| Sato, M | 1 |
| Sekine, I | 1 |
| Ito, Y | 1 |
| Fitchett, DH | 2 |
| Pathé, M | 1 |
| Pardy, R | 1 |
| Despas, P | 1 |
| Ginks, WR | 1 |
| Redwood, DR | 1 |
| Lewis, RP | 1 |
| Jain, AC | 1 |
| Harris, WS | 1 |
| Wirtzfeld, A | 1 |
| Klein, G | 1 |
| Himmler, FC | 1 |
| Schmidt, G | 1 |
| Kutschera, I | 1 |
| Sauer, E | 1 |
| Whiting, RB | 1 |
| García Puig, J | 1 |
| Gil Aguado, A | 1 |
| Arnalich, F | 1 |
| Gaspar, G | 1 |
| Anciones, B | 1 |
| Vázquez, JJ | 1 |
| Siegel, LA | 1 |
| Keung, E | 1 |
| Siskind, SJ | 1 |
| Forman, R | 1 |
| Feinberg, H | 1 |
| Efstathakis, D | 1 |
| Gogia, H | 1 |
| Mehra, A | 1 |
| Parikh, S | 1 |
| Raman, M | 1 |
| Ajit-Uppal, J | 1 |
| Johnson, JV | 1 |
| Giles, TD | 1 |
| Wang, SY | 1 |
| Manyari, DE | 1 |
| Scott-Douglas, N | 1 |
| Smiseth, OA | 1 |
| Smith, ER | 1 |
| Tyberg, JV | 2 |
| Baker, DW | 1 |
| Bottorff, M | 1 |
| Pitt, B | 1 |
| Akatsuka, N | 1 |
| Corbalán, R | 2 |
| Kunstmann, S | 1 |
| Jalil, J | 1 |
| Lee, TH | 1 |
| Hamilton, MA | 4 |
| Moriguchi, JD | 4 |
| Child, JS | 2 |
| Laks, H | 1 |
| Walden, JA | 2 |
| Ghose, JC | 1 |
| Chakraborty, S | 1 |
| Mondal, M | 1 |
| Bhandari, B | 1 |
| Goldsmith, SR | 1 |
| Carson, PE | 2 |
| Johnson, GR | 3 |
| Dunkman, WB | 6 |
| Fletcher, RD | 2 |
| Farrell, L | 3 |
| Cintron, G | 2 |
| Johnson, G | 13 |
| Francis, G | 3 |
| Cobb, F | 2 |
| Hughes, CV | 1 |
| Wong, M | 3 |
| Goldman, S | 2 |
| Smith, R | 4 |
| Cintron, GB | 1 |
| Orndorff, J | 1 |
| Simon, A | 1 |
| Shabetai, R | 2 |
| Loeb, H | 2 |
| Tristani, F | 3 |
| Rector, T | 1 |
| Fletcher, R | 2 |
| Cobb, FR | 1 |
| Hughes, V | 1 |
| Bhat, G | 2 |
| Lopez, B | 1 |
| Daniels, G | 1 |
| Henrick, A | 2 |
| Smith, B | 1 |
| Loeb, HS | 1 |
| Wilson, J | 1 |
| Cremo, R | 1 |
| Cohn, J | 1 |
| Cosín Aguilar, J | 1 |
| Cruz Fernández, JM | 1 |
| de Teresa Galván, E | 1 |
| Ferreira Montero, IJ | 1 |
| López-Sendón, J | 1 |
| Soler Soler, J | 1 |
| Tamargo Menéndez, J | 1 |
| Kurz, S | 1 |
| Rajagopalan, S | 1 |
| Thoenes, M | 1 |
| Berrington, WR | 1 |
| Thompson, JA | 1 |
| Freeman, BA | 1 |
| Harrison, DG | 1 |
| Häggström, J | 1 |
| Hansson, K | 1 |
| Karlberg, BE | 1 |
| Kvart, C | 1 |
| Madej, A | 1 |
| Olsson, K | 1 |
| King, D | 1 |
| Parker, JD | 1 |
| Parker, AB | 1 |
| Farrell, B | 1 |
| Parker, JO | 1 |
| Guazzi, M | 1 |
| Marenzi, G | 1 |
| Alimento, M | 1 |
| Contini, M | 1 |
| Agostoni, P | 1 |
| Steimle, AE | 1 |
| Chelimsky-Fallick, C | 2 |
| Kartashov, A | 1 |
| Tillisch, JH | 2 |
| Ellis, ML | 1 |
| Williamson, KM | 1 |
| Zhang, W | 1 |
| Sun, X | 1 |
| Zhao, X | 1 |
| Thorén, P | 1 |
| Hedner, T | 1 |
| Struthers, AD | 2 |
| Yee, KM | 1 |
| Semeniuk, LM | 1 |
| Belenkie, I | 1 |
| Harjai, KJ | 1 |
| Nunez, E | 1 |
| Stewart Humphrey, J | 1 |
| Turgut, T | 1 |
| Shah, M | 1 |
| Newman, J | 1 |
| Craven, R | 1 |
| Tsotetsi, OJ | 1 |
| Woodiwiss, AJ | 1 |
| Netjhardt, M | 1 |
| Qubu, D | 1 |
| Brooksbank, R | 1 |
| Norton, GR | 1 |
| Li, D | 1 |
| Shinagawa, K | 1 |
| Pang, L | 1 |
| Leung, TK | 1 |
| Cardin, S | 1 |
| Wang, Z | 1 |
| Nattel, S | 1 |
| Rich, MW | 1 |
| de Denus, S | 1 |
| Spinler, SA | 1 |
| Sterz, H | 1 |
| Kigawada, R | 1 |
| Tsuyusaki, T | 1 |
| Rubin, S | 1 |
| Gelberg, H | 1 |
| Mehta, J | 4 |
| Pepine, CJ | 3 |
| Conti, CR | 3 |
| Morand, P | 2 |
| Lavigne, G | 1 |
| Masson, D | 1 |
| Latour, F | 1 |
| Alison, D | 1 |
| Pailloncy, M | 1 |
| Fernandez, F | 1 |
| Lelguen, C | 1 |
| Datchary, J | 1 |
| Ponsonnaille, J | 1 |
| Gerbaux, A | 1 |
| Gras, H | 1 |
| Chazov, EI | 1 |
| Ruda, MIa | 1 |
| Halawa, B | 1 |
| Page, A | 1 |
| Larnaudie, B | 1 |
| Pic, A | 1 |
| Videau, P | 1 |
| Besse, P | 1 |
| Lloyd, EA | 1 |
| Romankiewicz, JA | 1 |
| Miller, RR | 2 |
| Werner, J | 2 |
| Greenberg, B | 2 |
| Hart, R | 1 |
| Awan, N | 1 |
| Francoual, M | 1 |
| Lellouche, D | 1 |
| Castaigne, A | 1 |
| Estampes, B | 1 |
| Vernant, P | 1 |
| Prati, PL | 1 |
| Manfrin, M | 1 |
| Imhof, P | 2 |
| Black, JR | 1 |
| Neto, JA | 1 |
| Oakley, CM | 1 |
| Goodwin, JF | 1 |
| Pfister, B | 1 |
| Gelberg, HJ | 1 |
| Armstrong, PW | 1 |
| Phaneuf, DC | 1 |
| Waters, DD | 1 |
| Théroux, P | 1 |
| Pelletier, G | 1 |
| Mizgala, HF | 1 |
| Arnold, S | 1 |
| Brundage, B | 1 |
| Iacona, M | 1 |
| Iturriaga, J | 1 |
| Laslett, LJ | 1 |
| Drew, D | 1 |
| Klausner, SC | 1 |
| Polansky, J | 1 |
| Zacherle, B | 1 |
| Klausner, S | 1 |
| Norman, A | 1 |
| Campbell, TJ | 1 |
| Komajda, M | 1 |
| Isnard, R | 1 |
| Lechat, P | 1 |
| Luu, M | 1 |
| Albanese, E | 1 |
| Kukin, ML | 1 |
| Manthey, J | 2 |
| Dietz, R | 2 |
| Opherk, D | 1 |
| Osterziel, KJ | 2 |
| Bauer, JA | 1 |
| Fung, HL | 1 |
| Binkley, PF | 1 |
| Hammer, DF | 1 |
| Haeusslein, EA | 1 |
| Schofield, PM | 1 |
| Brooks, NH | 1 |
| Lawrence, GP | 1 |
| Testa, HJ | 1 |
| Ward, C | 1 |
| Zhilin, SV | 1 |
| Vorob'ev, BI | 1 |
| Kastanaian, AA | 1 |
| Masalitinova, IV | 1 |
| Woo, M | 1 |
| Assmann, I | 1 |
| Haitas, B | 1 |
| Meyer, TE | 1 |
| Angel, ME | 1 |
| Reef, E | 1 |
| Bjornson, DC | 1 |
| Daniels, CE | 1 |
| Wertheimer, AI | 1 |
| Snowdon, DA | 1 |
| Litman, TJ | 1 |
| Sorkin, EM | 1 |
| Clissold, SP | 1 |
| Brogden, RN | 1 |
| Lee, WH | 1 |
| Kessler, PD | 1 |
| Gottlieb, SS | 1 |
| Mulrow, JP | 1 |
| Crawford, MH | 2 |
| Vine, DL | 1 |
| Roth, A | 1 |
| Hsueh, W | 1 |
| Freidenberger, L | 1 |
| Kiowski, W | 1 |
| Burkart, F | 1 |
| Röhrig, N | 1 |
| Haass, M | 1 |
| Schömig, A | 1 |
| Ruggie, N | 1 |
| Leon, CA | 1 |
| Pratt, CM | 1 |
| George, BL | 2 |
| Friedman, WF | 2 |
| Moriuchi, M | 1 |
| Kaseda, N | 1 |
| Tsuji, M | 1 |
| Tokutake, E | 1 |
| Sivkov, SI | 1 |
| Lesniak, EA | 1 |
| González-Juanatey, JR | 1 |
| Amaro Cendón, A | 1 |
| Vega Fernández, M | 1 |
| Gil de la Peña, M | 1 |
| Marantz, PR | 1 |
| Alderman, MH | 1 |
| Tobin, JN | 1 |
| Rothlin, ME | 1 |
| Sutton, FJ | 1 |
| Archibald, DG | 2 |
| Harston, WE | 2 |
| Tristani, FE | 2 |
| Jacobs, W | 2 |
| Flohr, KH | 2 |
| Daly, P | 1 |
| Cousineau, D | 1 |
| Burgess, JH | 1 |
| Zucker, MJ | 1 |
| Stasior, C | 1 |
| Talentowski, D | 1 |
| Stadnicki, R | 1 |
| Lesch, M | 1 |
| Desai, SP | 1 |
| Pierce, EC | 1 |
| Fleming, TC | 1 |
| Kirichenko, LL | 1 |
| Gaĭdukova, NI | 1 |
| Solov'eva, FV | 1 |
| Thorat, PB | 1 |
| Patel, KH | 1 |
| Appleton, S | 1 |
| Broudy, DR | 1 |
| Reinhart, S | 1 |
| Morris, C | 1 |
| Demots, H | 1 |
| Arriagada, D | 1 |
| Rodríguez, JA | 1 |
| Chamorro, G | 1 |
| Meleda, I | 1 |
| Casanegra, P | 1 |
| Valenzuela, P | 1 |
| Schroeder, JS | 1 |
| Shellock, FG | 1 |
| Abrams, J | 1 |
| Ruksin, VV | 1 |
| Krzyś, T | 1 |
| Kalawski, R | 1 |
| Flaczyński, K | 1 |
| Lenartowicz, I | 1 |
| Rosenblum, R | 1 |
| Baudouy, M | 1 |
| Camous, JP | 1 |
| Gibelin, P | 1 |
| Leborgne, L | 1 |
| Johnson, LE | 1 |
| Oliver, NB | 1 |
| Smucker, ML | 1 |
| Sanford, CF | 1 |
| Lipscomb, KM | 1 |
| Ludden, TM | 1 |
| Kennedy, GT | 1 |
| Fontaine, JL | 2 |
| Girardet, JP | 2 |
| Verlhac, S | 1 |
| Liechtmaneger, H | 1 |
| Koshlia, VI | 3 |
| Freis, ED | 2 |
| Arnold, OH | 1 |
| Amery, A | 1 |
| Fagard, R | 1 |
| Misotten, A | 1 |
| Slany, J | 1 |
| Johnsson, G | 1 |
| Fernandes, M | 1 |
| Kim, KE | 1 |
| Moyer, JH | 1 |
| Laidlaw, JC | 1 |
| Bock, KD | 1 |
| Vidt, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M[NCT03514108] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2018-03-01 | Recruiting | ||
| Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC)[NCT00512759] | Phase 4 | 781 participants (Actual) | Interventional | 2007-12-10 | Completed | ||
| The Effect of Aortic Impedance on Myocardial Relaxation[NCT00204984] | 17 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| [NCT00047775] | Phase 4 | 1,100 participants | Interventional | 2001-05-31 | Completed | ||
| A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction[NCT01822808] | Phase 3 | 500 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction[NCT01516346] | Phase 2 | 44 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Nitrative Stress in Heart Failure: The Cleveland Heart and Metabolic Prevention Study (CHAMPS)[NCT03012022] | 1,208 participants (Actual) | Observational | 2010-11-30 | Active, not recruiting | |||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| Innovative Strategies for Implementing New CHF Guideline Recommendations[NCT00012974] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Influence of ACE Genotype on Lung Diffusion at Rest and After Fluid Overload in Heart Failure Patients Treated With ACE-inhibitors[NCT00361127] | 100 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| Regional and Systemic Hemodynamic Effects of a Long-term Administration of Amlodipine in Patients With Chronic Heart Failure Treated With a Combination of Enalapril, Furosemide and Digoxin[NCT00151619] | Phase 2 | 7 participants (Actual) | Interventional | 1999-02-10 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Diastolic mitral annular velocity measured at the basal septal mitral annulus (NCT01516346)
Timeframe: 24 weeks
| Intervention | cm/s (Mean) |
|---|---|
| Isosorbide Dinitrate | 6.8 |
| Isosorbide Dinitrate + Hydralazine | 7.3 |
| Placebo | 6.5 |
LV mass measured by MRI, in grams normalized to height in meters raised to the 1.7 power (m^1.7) (NCT01516346)
Timeframe: 24 weeks
| Intervention | grams / meters ^1.7 (Mean) |
|---|---|
| Isosorbide Dinitrate | 68.2 |
| Isosorbide Dinitrate + Hydralazine | 66.2 |
| Placebo | 67.2 |
Myocardial extracellular volume, expressed as percent of total tissue volume, measured by MRI (T1 mapping pre and post-gadolinium administration) (NCT01516346)
Timeframe: 24 weeks
| Intervention | Percentage (Mean) |
|---|---|
| Isosorbide Dinitrate | 29.0 |
| Isosorbide Dinitrate + Hydralazine | 31.3 |
| Placebo | 29.5 |
Quality of life, assessed with the Kansas City cardiomyopathy questionnaire (overall summary score, which ranges from 0 to 100). Higher values imply better quality of life. (NCT01516346)
Timeframe: 24 weeks
| Intervention | Points on a scale (Mean) |
|---|---|
| Isosorbide Dinitrate | 62.1 |
| Isosorbide Dinitrate + Hydralazine | 44.9 |
| Placebo | 62.1 |
The dimensionless ratio of backward (reflected) to forward wave amplitude. Higher values imply more wave reflection. (NCT01516346)
Timeframe: 24 weeks
| Intervention | dimensionless ratio (Mean) |
|---|---|
| Isosorbide Dinitrate | 0.38 |
| Isosorbide Dinitrate + Hydralazine | 0.44 |
| Placebo | 0.37 |
99 reviews available for hydralazine and Cardiac Failure
| Article | Year |
|---|---|
A review on the clinical pharmacokinetics of hydralazine.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Heart Failure; Humans; Hydralazine; Hyperte | 2022 |
Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Female; Glomerulonephritis; Heart | 2021 |
Heart Failure Guidelines on Pharmacotherapy.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2017 |
Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction.
Topics: Clinical Trials as Topic; Drug Interactions; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrat | 2018 |
Heart Failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2018 |
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
Pharmacological management of chronic heart failure: old drugs, new drugs and new indications.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2013 |
Adjunctive therapy and management of the transition of care in patients with heart failure.
Topics: Adaptation, Psychological; Adrenergic beta-Antagonists; Alcohol Drinking; Ambulatory Care; Angiotens | 2014 |
Heart failure in African Americans: disparities can be overcome.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blac | 2014 |
Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitra | 2014 |
Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Mortality; Nitrates; | 2015 |
Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2016 |
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Recepto | 2016 |
Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Drug Combinations; Heart Failure; Humans; Hydralazine; Isos | 2008 |
Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
Topics: Black or African American; Black People; Drug Combinations; Evidence-Based Medicine; Heart Failure; | 2008 |
Genotyping the future: scientists' expectations about race/ ethnicity after BiDil.
Topics: Drug Combinations; Genetics, Population; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; P | 2008 |
[Recent findings on nitrates: their action, bioactivation and development of tolerance].
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Coronary Disease; Drug Tolerance; End | 2008 |
Observation unit management of acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Antihypertensive Agents; Centers for Medicare and Medica | 2009 |
Heart failure in women: a need for prospective data.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiac Pacing, A | 2009 |
Racial differences in heart failure therapeutics.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Black or African American; Drug Combinations; | 2010 |
Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions.
Topics: Animals; Black or African American; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as | 2011 |
The role of venodilators in the perioperative management of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hydral | 2012 |
Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con position.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blac | 2002 |
Clinical treatment regimens for chronic heart failure: a review.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2002 |
Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Cardioto | 2003 |
Congestive heart failure: what should be the initial therapy and why?
Topics: Adrenergic Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug The | 2002 |
How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine.
Topics: Black or African American; Cardiovascular Agents; Commerce; Drug Approval; Drug Combinations; Drug L | 2004 |
The impact of race on response to RAAS inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Clinical Trials as Topic; Diuretics, Osmotic | 2005 |
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Ho | 2005 |
Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.
Topics: Animals; Black or African American; Disease Models, Animal; Dose-Response Relationship, Drug; Drug A | 2005 |
A-HeFT: old dog, new endothelial tricks.
Topics: Black or African American; Drug Therapy, Combination; Endothelium, Vascular; Heart Failure; Humans; | 2005 |
Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure.
Topics: Heart Failure; Humans; Hydralazine; Lupus Erythematosus, Systemic; Risk Factors; Sex Factors; Vasodi | 2006 |
A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.
Topics: Black People; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; N | 2006 |
Pharmacotherapy implications of revised chronic heart failure guidelines.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Pharmacological treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.
Topics: Cardiac Output, Low; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Ni | 2006 |
Medicalisation of race.
Topics: Age Distribution; Aged; Antineoplastic Agents; Black or African American; Clinical Trials as Topic; | 2007 |
Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.
Topics: Black or African American; Disease Progression; Drug Combinations; Endothelium, Vascular; Genetic Pr | 2006 |
Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitra | 2007 |
African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans.
Topics: Adult; Aged; Black or African American; Drug Therapy, Combination; Endothelium, Vascular; Heart Fail | 2007 |
Evidence-based treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
Current concepts in the treatment of congestive heart failure.
Topics: Calcium Channel Blockers; Captopril; Digitalis Glycosides; Dipeptides; Diuretics; Enalapril; Enzyme | 1984 |
Vasodilator and inotropic agents in treatment of chronic cardiac failure: clinical experience and response in exercise performance.
Topics: Aerobiosis; Aminopyridines; Amrinone; Anaerobiosis; Cardiotonic Agents; Heart Failure; Hemodynamics; | 1981 |
[Treatment of heart failure in ischemic heart disease with beta-adrenostimulators and peripheral vasodilators].
Topics: Adrenergic beta-Agonists; Captopril; Cardiotonic Agents; Coronary Disease; Dobutamine; Dopamine; Hea | 1983 |
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
Mechanisms and implications of vasodilator tolerance in the treatment of congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Dr | 1981 |
Congestive heart failure in childhood and adolescence: recognition and management.
Topics: Adolescent; Captopril; Cardiomyopathies; Child; Digoxin; Dobutamine; Dopamine; Echocardiography; Ele | 1983 |
Vasodilator therapy in chronic congestive heart failure.
Topics: Captopril; Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralaz | 1983 |
Hydralazine in heart failure.
Topics: Animals; Aortic Valve Insufficiency; Cardiac Output; Cats; Coronary Circulation; Exercise Test; Hear | 1983 |
[Vasodilator agents in the treatment of cardiac insufficiency].
Topics: Captopril; Dihydralazine; Heart Failure; Humans; Hydralazine; Nitroglycerin; Nitroprusside; Phentola | 1984 |
[Treatment of heart failure with vasodilators].
Topics: Captopril; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Heart Failure; Heart Function Tests; | 1980 |
Vasodilator therapy for chronic heart failure.
Topics: Captopril; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglyceri | 1980 |
[Peripheral vasodilator agents in cardiology].
Topics: Clinical Trials as Topic; Coronary Vessels; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocar | 1980 |
Vasodilator therapy of congestive heart failure.
Topics: Aortic Valve Insufficiency; Captopril; Dobutamine; Heart Failure; Humans; Hydralazine; Isosorbide Di | 1980 |
Cardiovascular clinical pharmacology of impedance reducing agents.
Topics: Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Phentolamine; Prazosin; | 1981 |
[Peripheral vasodilators in the treatment of heart failure].
Topics: Cardiac Output; Cardiomyopathies; Coronary Circulation; Droperidol; Heart Failure; Humans; Hydralazi | 1982 |
Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Enalapril; Exercise; Felodipine; Heart Failure; | 1994 |
Plasma norepinephrine and mortality.
Topics: Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Norepinephrine; Prognosis; Symp | 1995 |
Optimizing the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent | 1994 |
Management of heart failure. I. Pharmacologic treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Decision Support Techniques; Digoxin; Diuretics; Heart Fai | 1994 |
[Vasodilator therapy in cardiac failure].
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitroglycerin | 1993 |
[Vasodilator agents in chronic heart failure: which is the best option?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Clinical Trials as Topic; Drug Therapy, C | 1993 |
[Neurohormonal factors in heart failure. I].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Autonomic | 1996 |
Is there a role for endothelin in the natural history of heart failure?
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Endothelin Receptor Antagonists; | 1996 |
Diagnosis and management of heart failure in the elderly.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Digoxin; Diur | 1996 |
Rationalizing the heart failure trials: from theory to practice.
Topics: Adrenergic beta-Antagonists; Amiodarone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti- | 1997 |
Can drug effects on mortality in heart failure be predicted by any surrogate measure?
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Biomarkers; Calcium Ch | 1997 |
Left ventricle and arteries: structure, function, hormones, and disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine Vasopressin; Dr | 2001 |
Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2001 |
Management of heart failure in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
[New aspects in the treatment of acute cardiac insufficiency].
Topics: Adrenergic beta-Antagonists; Clonidine; Diazoxide; Digitalis Glycosides; Diuretics; Droperidol; Fent | 1978 |
[Phentolamine, hydralazine and alpha blockaders].
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Heart Failure; Humans; Hydralazine; Phentolamine; Vasc | 1978 |
Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
Topics: Aorta; Cardiac Output; Chronic Disease; Heart; Heart Failure; Heart Ventricles; Hemodynamics; Humans | 1978 |
[Use of vasodilator agents in circulatory insufficienty].
Topics: Blood Circulation; Dihydralazine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitro | 1979 |
The use of vasodilator agents in the treatment of heart failure.
Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela | 1979 |
Pharmacology and clinical use of drugs in hypertensive emergencies.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Aorta; Brain Diseases; Cerebral Hemorrhage; Diazox | 1977 |
Afterload reduction in the management of congestive heart failure following acute myocardial infarction.
Topics: Acute Disease; Dopamine; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Infarction; Ni | 1978 |
Oral vasodilator therapy for chronic heart failure: a plea for caution.
Topics: Cardiac Output; Chronic Disease; Forecasting; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin | 1978 |
Vasodilator therapy of cardiac failure: (first of two parts).
Topics: Blood Vessels; Diuretics; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Hydralazine; Nitrat | 1977 |
[Vasodilators: treatment of cardiac insufficiency].
Topics: Heart Failure; Humans; Hydralazine; Mitral Valve Insufficiency; Myocardial Infarction; Nitroglycerin | 1977 |
[Vasodilator agents in the treatment of heart failure].
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Minoxidil; Nitroglycerin; Nitroprusside; P | 1978 |
[Treatment of cardiac failure with vasodilators (author's transl)].
Topics: Cardiac Glycosides; Diuretics; Drug Therapy, Combination; Heart Failure; Hydralazine; Hypotension; I | 1978 |
[Nitrate derivatives and cardiac insufficiency].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Drug Tolerance; Heart Fai | 1992 |
Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
Topics: Enalapril; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Prazosin; Surviva | 1991 |
Studies of Left Ventricular Dysfunction (SOLVD)--new hope for heart failure.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbid | 1991 |
[The extension of heart failure therapy with vasodilators].
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Drug Therapy, Combination; Heart | 1990 |
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
Topics: Absorption; Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Platelets; Calcium Channel | 1985 |
Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.
Topics: Heart Failure; Humans; Hydralazine | 1989 |
Heart failure management: the impact of drug therapy on survival.
Topics: Captopril; Clinical Trials as Topic; Digitalis Glycosides; Diuretics; Enalapril; Heart Failure; Huma | 1988 |
Congestive heart failure.
Topics: Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic | 1986 |
Potentially deleterious effects of long-term vasodilator therapy in patients with heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; M | 1987 |
Vasodilators for chronic congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Hydralaz | 1988 |
Diagnostic heterogeneity in clinical trials for congestive heart failure.
Topics: Amrinone; Clinical Trials as Topic; Digoxin; Heart Failure; Humans; Hydralazine; Metoprolol; Researc | 1988 |
Vasodilator therapy.
Topics: Administration, Oral; Captopril; Cardiac Output; Dose-Response Relationship, Drug; Double-Blind Meth | 1986 |
Role of isosorbide dinitrate in management of chronic congestive heart failure.
Topics: Administration, Oral; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug | 1985 |
Combination therapy with isosorbide dinitrate: current status and the future.
Topics: Angina Pectoris; Coronary Vasospasm; Diltiazem; Drug Therapy, Combination; Esophageal Achalasia; Exe | 1985 |
Effectiveness of drug therapy in hypertension: present status. A review.
Topics: Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Eye Diseases; Ganglionic Block | 1971 |
[Cardiac complications in hypertension].
Topics: Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Circulation; Coronary Diseas | 1972 |
Hypertensive emergencies.
Topics: Acute Kidney Injury; Adrenal Gland Neoplasms; Antihypertensive Agents; Aortic Aneurysm; Blood Volume | 1974 |
80 trials available for hydralazine and Cardiac Failure
| Article | Year |
|---|---|
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr
Topics: Aged; Chronic Disease; Denmark; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; H | 2021 |
Combined effects of hydralazine and nitrate on serum biochemistry and left ventricular remodeling in chronic heart failure patients.
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Humans; Hydralazine; Intercellular Signaling Peptide | 2021 |
Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial.
Topics: Adrenergic beta-Antagonists; Black or African American; Cause of Death; Double-Blind Method; Drug Th | 2018 |
Left ventricular responses to acute changes in late systolic pressure augmentation in older adults.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Disease Progression; Dose-Respons | 2013 |
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial.
Topics: Black or African American; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up St | 2014 |
G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.
Topics: Analysis of Variance; Black or African American; Disease-Free Survival; Drug Combinations; Female; G | 2014 |
Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF).
Topics: Acute Disease; Adult; Africa South of the Sahara; Aged; Black People; Double-Blind Method; Heart Fai | 2016 |
Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Echocardiogr | 2017 |
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.
Topics: Black People; Blood Pressure; Diastole; Drug Combinations; Female; Gene Frequency; Genotype; Heart F | 2009 |
Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure.
Topics: Adenosine Diphosphate; Aged; Blood; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Re | 2010 |
Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT).
Topics: Atrial Fibrillation; Black or African American; Drug Combinations; Female; Follow-Up Studies; Heart | 2011 |
Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial.
Topics: Age Factors; Aged; Aging; Black or African American; Double-Blind Method; Drug Therapy, Combination; | 2012 |
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
Topics: Adolescent; Adult; Aged; Black People; Double-Blind Method; Drug Combinations; Female; Heart Failure | 2002 |
The African-American Heart Failure Trial: background, rationale and significance.
Topics: Black or African American; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Hydralaz | 2002 |
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Adult; Aged; Black People; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female | 2004 |
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Adult; Aged; Black People; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female | 2004 |
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Adult; Aged; Black People; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female | 2004 |
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Adult; Aged; Black People; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female | 2004 |
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
Topics: Adult; Aged; Arthralgia; Biomarkers; Black or African American; Cardiovascular Agents; Cause of Deat | 2007 |
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
Topics: Adult; Aged; Black or African American; Drug Therapy, Combination; Female; Heart Failure; Humans; Hy | 2007 |
Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).
Topics: Administration, Oral; Black or African American; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2007 |
Dose-dependent haemodynamic response to prenalterol in patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Cardiac Catheterization; Cardiac Output; Dose-Respon | 1982 |
Central and regional hemodynamic effects and neurohumoral consequences of minoxidil in severe congestive heart failure and comparison to hydralazine and nitroprusside.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Heart Failure; Hemodynamics; Hum | 1983 |
Hemodynamic trial of sequential treatment with diuretic, vasodilator, and positive inotropic drugs in left ventricular failure following acute myocardial infarction.
Topics: Adrenergic beta-Agonists; Adult; Cardiotonic Agents; Drug Therapy, Combination; Furosemide; Heart Fa | 1984 |
[Long-term drug treatment of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Captopril; Heart Failure; Hemodynamics; Humans; Hydralazine; Nitroglyce | 1984 |
Clinical efficacy of hydralazine in chronic heart failure: one-year double-blind placebo-controlled study.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Heart Failure; Humans; Hydralazine; Mal | 1984 |
Hydralazine therapy in chronic congestive heart failure. Sustained central and regional hemodynamic responses.
Topics: Administration, Oral; Cardiac Output; Chronic Disease; Clinical Trials as Topic; Double-Blind Method | 1984 |
Loss of effectiveness of dihydralazine in the long-term treatment of chronic heart failure.
Topics: Adult; Aged; Cardiac Output; Chronic Disease; Coronary Circulation; Coronary Disease; Dihydralazine; | 1984 |
Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction.
Topics: Adult; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Furosemide; Heart Failure; Heart R | 1983 |
Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy.
Topics: Aged; Cardiomyopathy, Hypertrophic; Drug Combinations; Female; Heart; Heart Failure; Hemodynamics; H | 1983 |
[Peripheral vasodilator agents in cardiology].
Topics: Clinical Trials as Topic; Coronary Vessels; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocar | 1980 |
[Current state of the treatment of arterial hypertension].
Topics: Adult; Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Heart Failure; Humans; Hydralazine | 1980 |
Variable hemodynamic response to oral hydralazine in patients with refractory congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Female; | 1980 |
Hydralazine versus placebo in CHF - preliminary results from a multicenter long term study in Sweden.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Heart Failure; Hemo | 1981 |
Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study.
Topics: Aged; Captopril; Coronary Disease; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Hu | 1982 |
Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Exercise Te | 1982 |
Circulatory improvement after hydralazine or isosorbide dinitrate administration in patients with heart failure. Effect on metabolic responses to submaximal exercise.
Topics: Adult; Aged; Cardiac Output; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Di | 1981 |
Effect of hydralazine on renal failure in patients with congestive heart failure.
Topics: Aged; Blood Pressure; Body Weight; Creatinine; Heart Failure; Heart Rate; Humans; Hydralazine; Kidne | 1980 |
[Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)].
Topics: Adult; Aged; Dihydralazine; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; | 1980 |
Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Drug Therapy, Combination; Drug Tolerance; Female | 1995 |
Plasma norepinephrine and mortality.
Topics: Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Norepinephrine; Prognosis; Symp | 1995 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure.
Topics: Adult; Aged; Captopril; Chi-Square Distribution; Chronic Disease; Double-Blind Method; Drug Therapy, | 1993 |
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
Topics: Atrial Fibrillation; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isoso | 1993 |
The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male | 1993 |
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male | 1993 |
Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Age Factors; Aged; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorb | 1993 |
Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male | 1993 |
Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
Topics: Cause of Death; Death, Sudden, Cardiac; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; | 1993 |
Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
Topics: Death, Sudden, Cardiac; Drug Therapy, Combination; Electrocardiography, Ambulatory; Enalapril; Heart | 1993 |
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male | 1993 |
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Arrhythmias, Cardiac; Cardiomegaly; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hyd | 1993 |
Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Topics: Anaerobic Threshold; Drug Therapy, Combination; Enalapril; Exercise Test; Exercise Tolerance; Heart | 1993 |
Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Echocardiography; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbi | 1993 |
Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Topics: Attitude to Health; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosor | 1993 |
Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbid | 1993 |
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Cerebrovascular Disorders; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; | 1993 |
Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT)
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; He | 1996 |
Prevention of nitrate tolerance with concomitant administration of hydralazine.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Tolera | 1996 |
The effect of hydralazine on the development of tolerance to continuous nitroglycerin.
Topics: Administration, Cutaneous; Adult; Blood Pressure; Double-Blind Method; Drug Tolerance; Female; Heart | 1997 |
Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood-Air Barrier; Bradykinin; Cyclooxygena | 1997 |
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Double-Blind Method; Drug Therapy, Combinati | 1999 |
Immediate effects of hydralazine-isosorbide dinitrate combination on exercise capacity and exercise hemodynamics in patients with left ventricular failure.
Topics: Adult; Aged; Drug Therapy, Combination; Exercise Test; Heart Failure; Hemodynamics; Humans; Hydralaz | 1979 |
Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial.
Topics: Actuarial Analysis; Captopril; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide | 1992 |
V-HeFT positive for enalapril.
Topics: Adolescent; Adult; Aged; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; | 1991 |
Studies of Left Ventricular Dysfunction (SOLVD)--new hope for heart failure.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbid | 1991 |
Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine.
Topics: Adult; Aged; Captopril; Cardiomyopathy, Dilated; Chronic Disease; Coronary Disease; Exercise Test; F | 1991 |
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Chronic Disease; Death, Sudden; Double-Blind Method; Drug Administration Sc | 1991 |
[Differential use of peripheral vasodilators in the treatment of chronic circulatory failure in patients with mitral valve insufficiency].
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Hydralazine; | 1990 |
Statistical significance of Veterans Administration Vasodilator Heart Failure Trial results.
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Prazosin; Research Design; Statistics as T | 1990 |
Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Heart Failur | 1990 |
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
Topics: Absorption; Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Platelets; Calcium Channel | 1985 |
Heart failure management: the impact of drug therapy on survival.
Topics: Captopril; Clinical Trials as Topic; Digitalis Glycosides; Diuretics; Enalapril; Heart Failure; Huma | 1988 |
Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure.
Topics: Adult; Aged; Aldosterone; Catecholamines; Drug Therapy, Combination; Epinephrine; Female; Heart Fail | 1986 |
Role of vasodilators in the treatment of congestive heart failure.
Topics: Captopril; Clinical Trials as Topic; Dipeptides; Double-Blind Method; Enalapril; Heart Failure; Huma | 1985 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide | 1988 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Exercise Test; Follow-Up Studies; Heart Failure | 1986 |
Aspects on "traditional" vasodilators in the treatment of chronic heart failure.
Topics: Cardiac Output; Clinical Trials as Topic; Double-Blind Method; Heart; Heart Failure; Hemodynamics; H | 1986 |
Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Heart Failure | 1987 |
Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.
Topics: Adult; Age Factors; Aged; Aneurysm; Atrial Fibrillation; Blood Glucose; Blood Pressure; Cerebrovascu | 1972 |
Alprenolol in hypertension.
Topics: Aged; Alprenolol; Benzothiadiazines; Chlorthalidone; Clinical Trials as Topic; Digitalis; Diuretics; | 1974 |
Hypertension: a challenge in preventive medicine.
Topics: Age Factors; Attitude to Health; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disea | 1974 |
326 other studies available for hydralazine and Cardiac Failure
| Article | Year |
|---|---|
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonis | 2022 |
Cardiologists' Perspectives on BiDil and the Use of Race in Drug Prescribing.
Topics: Cardiologists; Cross-Sectional Studies; Drug Prescriptions; Heart Failure; Humans; Hydralazine; Isos | 2022 |
Inpatient Quality-of-Care Measures for Heart Failure: Treatment Gaps and Opportunities in the Contemporary Era.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2022 |
When the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark.
Topics: Denmark; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2023 |
Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a "2-Hit" Murine Model.
Topics: Animals; Disease Models, Animal; Drinking Water; Heart Failure; Hydralazine; Male; Mice; Mice, Inbre | 2023 |
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Black or African America | 2019 |
Captopril Versus Hydralazine-Isosorbide Dinitrate Vasodilator Protocols in Patients With Acute Decompensated Heart Failure Transitioning From Sodium Nitroprusside.
Topics: Adult; Aftercare; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captop | 2021 |
Vericiguat, organic nitrates, and heart failure in African Americans.
Topics: Black or African American; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hydralazine; Isoso | 2021 |
Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.
Topics: Adult; Black or African American; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, | 2017 |
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure.
Topics: Adult; Aged; Black or African American; Cardiotonic Agents; Drug Combinations; Female; Heart Failure | 2017 |
The Paradox in Demonstrating Hydralazine-Nitrate Efficacy.
Topics: Black or African American; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Treatment Outco | 2017 |
Adherence to the evidence-based heart failure drug treatment: Are there sex-specific differences among new users?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2018 |
Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey.
Topics: Black People; Cardiovascular Agents; Cross-Sectional Studies; Databases, Pharmaceutical; Drug Combin | 2019 |
Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Middle Aged; Nitra | 2019 |
Treatments for heart failure. Many therapies can be effective, but care must be individualized.
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiac Surgical Procedures; Cardiovascular Agents; Combine | 2012 |
Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.
Topics: Aged; Aged, 80 and over; Black or African American; Chi-Square Distribution; Drug Combinations; Drug | 2013 |
Nitrate therapy for heart failure: benefits and strategies to overcome tolerance.
Topics: Drug Tolerance; Heart Failure; Humans; Hydralazine; Nitrates; Vasodilator Agents | 2013 |
Treatment of pre-existing cardiomyopathy during pregnancy.
Topics: Adult; Antihypertensive Agents; Cardiomyopathy, Dilated; Female; Follow-Up Studies; Heart Failure; H | 2014 |
Genetic mechanisms possibly leading to racially different responses to nitrate therapy.
Topics: Black or African American; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2014 |
Current perspectives on hydralazine and nitrate therapies in heart failure.
Topics: Age Factors; Drug Combinations; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Ma | 2014 |
Polymorphic variation in the G-protein beta-3 subunit gene and response to BiDil in A-HeFT: Basis for an African-American pharmacogenetic advantage to nitric oxide donor therapy?
Topics: Female; Heart Failure; Heterotrimeric GTP-Binding Proteins; Humans; Hydralazine; Isosorbide Dinitrat | 2014 |
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Disease Progression; Drug Combinations; Female; Gu | 2016 |
Making Medicine Precise and Personalized: What Can We Learn from the Past?
Topics: Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Practic | 2016 |
PGX: Pharmacogenomics During Generation X.
Topics: Anticoagulants; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heart Failure; H | 2016 |
Dilemmas With Race and Heart Failure Treatment.
Topics: Black or African American; Clinical Decision-Making; Drug Combinations; Health Status Disparities; H | 2016 |
INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2016 |
Introduction: Facts and fictions: BiDil and the resurgence of racial medicine.
Topics: Black People; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Vasodilat | 2008 |
Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients.
Topics: Black People; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinit | 2008 |
Popular representations of race: the news coverage of BiDil.
Topics: Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mass Media; Racial Grou | 2008 |
"Special treatment": BiDil, Tuskegee, and the logic of race.
Topics: Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Ethics, Medic | 2008 |
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Topics: Adult; Aged; Black or African American; Clinical Trials, Phase III as Topic; Drug Combinations; Drug | 2008 |
From the editors.
Topics: Analgesia; Bioethical Issues; Bioethics; Black or African American; Conscience; Drug Combinations; E | 2009 |
Race-based medicine and justice as recognition: exploring the phenomenon of BiDil.
Topics: Black or African American; Cardiovascular Agents; Drug Approval; Drug Combinations; Drug Design; Eth | 2009 |
Pharmacogenetics, race and global injustice.
Topics: Black or African American; Delivery of Health Care; Developing Countries; Drug Combinations; Heart F | 2008 |
Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Interactions; D | 2008 |
Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Card | 2009 |
Have we witnessed the rise and fall of race-specific drugs?
Topics: Black or African American; Drug Combinations; Heart Failure; Hispanic or Latino; Humans; Hydralazine | 2009 |
Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.
Topics: Aged; Black or African American; Drug Combinations; Drug Prescriptions; Female; Heart Failure; Hispa | 2009 |
Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cytokines; Diastole; Drug Therapy, | 2009 |
Symptomatic and hemodynamic benefit of pentaerythrityl tetranitrate and hydralazine in a case of congestive heart failure.
Topics: Aged; Cardiomyopathy, Dilated; Drug Therapy, Combination; Dyspnea; Heart Failure; Hemodynamics; Huma | 2009 |
Primary care physicians' attitudes regarding race-based therapies.
Topics: Adult; Aged; Attitude of Health Personnel; Black People; Drug Combinations; Female; Focus Groups; He | 2010 |
Clinical pearls in cardiology.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiomyopathy, Dilated; Diuretics; Female; Heart Failure | 2010 |
Isosorbide dinitrate and hydralazine as therapy for African Americans with heart failure; a failed paradigm?
Topics: Black or African American; Cardiology; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosor | 2009 |
Grassroots marketing in a global era: more lessons from BiDil.
Topics: Black People; Drug Combinations; Drug Industry; Heart Failure; Humans; Hydralazine; Isosorbide Dinit | 2011 |
Natural history of end-stage LV dysfunction: has it improved from the classic Franciosa and Cohn Graph?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiac Resynch | 2011 |
Letter by Taylor et al regarding article, "Hydralazine and isosorbide dinitrate in heart failure: historical perspectives, mechanisms, and future directions".
Topics: Animals; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2011 |
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Cyclic GMP-Dependent Protein Kinase Typ | 2012 |
American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echoca | 2003 |
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Data Interpretation, Statistical; D | 2003 |
[Pharmacodynamic differentiation of apresoline, serpasil and chlorpromazine by their effect on water retention in the rat].
Topics: Animals; Antihypertensive Agents; Chlorpromazine; Heart Failure; Hydralazine; Kidney; Rats; Reserpin | 1955 |
ACUTE GLOMERULONEPHRITIS.
Topics: Blood Chemical Analysis; Child; Convalescence; Edema; Electrocardiography; Erythromycin; Glomerulone | 1964 |
THE HEART AND ACUTE GLOMERULONEPHRITIS.
Topics: Child; Diet, Sodium-Restricted; Digitalis Glycosides; Drug Therapy; Glomerulonephritis; Heart Diseas | 1964 |
Reversal of heart failure remodeling: is it maintained?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Cardiomyopathies; Echocardiography; Female | 2003 |
Getting the numbers right: statistical mischief and racial profiling in heart failure research.
Topics: Adult; Aged; Black or African American; Clinical Trials as Topic; Data Interpretation, Statistical; | 2003 |
Race-based therapeutics.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Drug Approval; Drug Combinations; Drug Indus | 2004 |
Nitroso-redox balance in the cardiovascular system.
Topics: Black People; Cardiovascular System; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbi | 2004 |
Postcards: race and medicine in the 21st century.
Topics: Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Heart Failure | 2004 |
Color blind.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitra | 2004 |
Studying treatment of heart failure in blacks.
Topics: Black People; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; M | 2005 |
A cure for a race? Heart drug findings set off ethics debate.
Topics: Black or African American; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; D | 2004 |
The year in heart failure: 2004.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Defibrillator | 2005 |
Heart failure after Caesarean section for twin delivery.
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Cardiotonic Agents; Catheterization, Swan-Ganz; | 2004 |
Isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Black People; Coronary Disease; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Hyper | 2005 |
Isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Black People; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; L | 2005 |
Isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Black People; Data Interpretation, Statistical; Drug Therapy, Combination; Heart Failure; Humans; Hy | 2005 |
Isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Black People; Calcium Channel Blockers; Drug Therapy, Combination; Heart Failure; Humans; Hydralazin | 2005 |
Race and a heart drug.
Topics: Black People; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; M | 2005 |
U.S. to review drug intended for one race.
Topics: Black or African American; Cardiovascular Agents; Clinical Trials as Topic; Drug Approval; Drug Comb | 2005 |
Drug targeting: is race enough?
Topics: Asian People; Black or African American; Drug Combinations; Drug Industry; ErbB Receptors; Gefitinib | 2005 |
Pharmacogenetics and ethnically targeted therapies: racial drugs need to be put in context.
Topics: Conflict of Interest; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; P | 2005 |
F.D.A. panel approves heart remedy for blacks.
Topics: Advisory Committees; Black or African American; Drug Approval; Drug Combinations; Heart Failure; Hum | 2005 |
F.D.A. approves a heart drug for African-Americans.
Topics: Black or African American; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Iso | 2005 |
Misreading race and genomics after BiDil.
Topics: Black or African American; Cardiovascular Agents; Drug Approval; Drug Combinations; Genomics; Heart | 2005 |
Race, drugs, and heart failure.
Topics: Aged; Aged, 80 and over; Black People; Drug Combinations; Drug Therapy, Combination; Female; Heart F | 2005 |
Color blind, or just plain blind?
Topics: Arginine; Black People; Delayed-Action Preparations; Drug Combinations; Heart Failure; Humans; Hydra | 2005 |
Maker of heart drug intended for blacks bases price on patients' wealth.
Topics: Black or African American; Costs and Cost Analysis; Drug Combinations; Drug Costs; Drug Industry; He | 2005 |
Illuminating BiDil.
Topics: Black or African American; Drug Approval; Drug Combinations; Genetic Predisposition to Disease; Hear | 2005 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2005 |
New heart-failure therapy takes race into account.
Topics: Black People; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; | 2005 |
Drug success signals a new trend. A "race-based" medication is a step toward individualized care.
Topics: Black People; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hydralazine; Isoso | 2005 |
Drugs tailored to race move a step closer to reality.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitra | 2005 |
Report from the Cardiovascular and Renal Drugs Advisory Committee: US Food and Drug Administration; June 15-16, 2005; Gaithersburg, Md.
Topics: Antihypertensive Agents; Black People; Cardiovascular Agents; Drug Combinations; Drug Labeling; Epid | 2005 |
BiDil for heart failure.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Black People; Drug Combinations; Heart Failure; Human | 2005 |
Race as a proxy for drug response: the dangers and challenges of ethnic drugs.
Topics: Black or African American; Clinical Trials as Topic; Commerce; Conflict of Interest; Drug Combinatio | 2004 |
Update on outpatient treatment of systolic heart failure.
Topics: Ambulatory Care; Black or African American; Diuretics; Drug Therapy, Combination; Heart Failure; Hum | 2005 |
Approval of drug marketed to African Americans raises political, economic issues. Study criticizes manufacturer for re-branding generic drug with race-specific indication.
Topics: Black or African American; Drug Approval; Drug Combinations; Drug Industry; Economics; Heart Failure | 2005 |
BiDil's impact.
Topics: Black or African American; Drug Approval; Drug Combinations; Genetic Predisposition to Disease; Hear | 2005 |
Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Animals; Antioxidants; Cell Adhesion | 2005 |
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.
Topics: Black People; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Cost | 2005 |
Gray area for new heart failure drug. Although the FDA approved BiDil for blacks with heart failure, it may work in anyone.
Topics: Black People; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinit | 2005 |
A look back at the most influential drug approvals of 2005.
Topics: Amyloid; Analgesics; Anticonvulsants; Antiparkinson Agents; Diabetes Mellitus, Type 2; Diphtheria-Te | 2006 |
Hydralazine-induced lupus.
Topics: Female; Heart Failure; Humans; Hydralazine; Lupus Erythematosus, Systemic; Risk Factors; Vasodilator | 2006 |
Should drug therapy be personalized based on race?
Topics: Antihypertensive Agents; Black or African American; Diuretics; Drug Therapy; Ethnicity; Heart Failur | 2006 |
The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?
Topics: Antihypertensive Agents; Black or African American; Diuretics, Osmotic; Drug Combinations; Heart Fai | 2006 |
"Racially-tailored" medicine unraveled.
Topics: Cardiovascular Agents; Civil Rights; Delivery of Health Care; Drug Combinations; Ethics Committees, | 2005 |
Novel heart failure drug may offer options for you.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitra | 2005 |
Food & Drug Administration panel approves heart failure medication aimed at African-Americans.
Topics: Advisory Committees; Black or African American; Drug Approval; Drug Combinations; Heart Failure; Hum | 2005 |
Using race in clinical research to develop tailored medications. Is the FDA encouraging discrimination or eliminating traditional disparities in health care for African Americans?
Topics: Black or African American; Clinical Protocols; Clinical Trials as Topic; Drug Approval; Drug Combina | 2006 |
Prescribing BiDil: is it black and white?
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Drug Approval; Drug Combinations; Enalapril; | 2006 |
Diagnosis and management of chronic heart failure.
Topics: Adult; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Practice | 2006 |
p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Female; Heart Failure; Hydralazine; | 2006 |
Response to the February 2006 Journal of Cardiac Failure Editor's comment.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitra | 2006 |
The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial.
Topics: Biomedical Research; Black or African American; Civil Rights; Drug Combinations; Ethical Analysis; E | 2006 |
Race, money and medicines.
Topics: Biomedical Research; Civil Rights; Drug Approval; Drug Combinations; Drug Industry; Ethical Analysis | 2006 |
BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval.
Topics: Black People; Cardiovascular Agents; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydral | 2007 |
BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
Topics: Black People; Cardiovascular Agents; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydral | 2007 |
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.
Topics: Adult; Aged; Antihypertensive Agents; Black or African American; Blood Pressure; Comorbidity; Drug C | 2007 |
Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure.
Topics: Black or African American; Chemistry, Pharmaceutical; Drug Combinations; Heart Failure; Humans; Hydr | 2007 |
From disparity to difference: how race-specific medicines may undermine policies to address inequalities in health care.
Topics: Black or African American; Drug Combinations; Ethnicity; Health Policy; Health Services Accessibilit | 2005 |
There is no scientific rationale for race-based research.
Topics: Biomarkers; Biomedical Research; Black or African American; Clinical Trials as Topic; Drug Combinati | 2007 |
What's right (and wrong) with racially stratified research and therapies.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biomedical Research; Black or African American | 2007 |
BiDil: primary care physicians first and cardiologist when?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Ca | 2007 |
The paradox of race in the Bidil debate.
Topics: Black or African American; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Iso | 2007 |
BiDil for heart failure in black patients.
Topics: Black People; Cardiovascular Agents; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydral | 2007 |
BiDil for heart failure in black patients.
Topics: Black People; Cardiovascular Agents; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydral | 2007 |
Race in a bottle. Drugmakers are eager to develop medicines targeted at ethnic groups, but so far they have made poor choices based on unsound science.
Topics: Black or African American; Drug Combinations; Drug Design; Ethnicity; Heart Diseases; Heart Failure; | 2007 |
Bidil: recontextualizing the race debate.
Topics: Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Heart Failure | 2008 |
[Special place of PETN among nitrates. No tolerance development, fewer headaches].
Topics: Angina Pectoris; Antihypertensive Agents; Drug Therapy, Combination; Drug Tolerance; Headache; Heart | 2008 |
BiDil flops.
Topics: Black People; Drug Industry; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Marketing; Ma | 2008 |
Hypertensive vascular disease. The long term effect of rapid repeated reductions of arterial pressure with diazoxide.
Topics: Adult; Chlorthalidone; Diazoxide; Female; Heart Failure; Humans; Hydralazine; Hypertension; Injectio | 1967 |
Drugs and the heart. VI. Vasodilating drugs.
Topics: Cardiotonic Agents; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Hypertension; | 1980 |
[Vasodilators in heart failure? Basic principles and its role in practice].
Topics: Adrenergic alpha-Antagonists; Captopril; Diazoxide; Furosemide; Heart Failure; Humans; Hydralazine; | 1981 |
Short and long-term effects of hydralazine and combined hydralazine and prenalterol therapy in patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Blood Pressure; Cardiac Catheterization; Cardiac Out | 1982 |
Electrophysiologic properties of hydralazine in man.
Topics: Aged; Bundle of His; Electrophysiology; Female; Heart Conduction System; Heart Diseases; Heart Failu | 1980 |
[Alternatives to digitalis therapy?].
Topics: Albuterol; Captopril; Dobutamine; Dopamine; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; | 1981 |
[Oral hydralazine in severe congestive heart failure. Echographic and first-step sequential gammagraphy using Tc 99m-albumin].
Topics: Adult; Aged; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; Middl | 1982 |
[Vasodilator drugs in the therapy of chronic congestive heart failure. Clinico-case contribution].
Topics: Blood Pressure; Cardiomegaly; Chronic Disease; Drug Evaluation; Heart; Heart Failure; Humans; Hydral | 1983 |
Myocardial function structure and collagen in the spontaneously hypertensive rat: progression from compensated hypertrophy to haemodynamic impairment.
Topics: Animals; Body Weight; Cardiomegaly; Collagen; Guanethidine; Heart Failure; Hydralazine; Hypertension | 1984 |
Treatment of acute and chronic congestive heart failure by vasodilator-afterload reduction.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Cardiac Output; Chronic Disease; Diastole; H | 1980 |
Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Heart Ventricles; Hemodynamics; | 1982 |
Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response.
Topics: Adult; Aged; Cardiac Catheterization; Cardiac Output; Chronic Disease; Drug Evaluation; Female; Hear | 1983 |
Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition.
Topics: Adult; Aged; Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardioto | 1984 |
Vasodilator therapy for acute myocardial infarction and chronic congestive heart failure.
Topics: Captopril; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Infarction; Prazosin; Region | 1983 |
New approaches to managing congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Prazosin; Proline; Quinazolines | 1983 |
Converting-enzyme inhibitor therapy for chronic heart failure.
Topics: Captopril; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Heart Fai | 1983 |
Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure.
Topics: Aged; Blood Pressure; Captopril; Cardiac Output; Drug Therapy, Combination; Female; Heart Failure; H | 1983 |
[Alternatives to digitalis therapy].
Topics: Aminopyridines; Amrinone; Captopril; Catecholamines; Diuretics; Heart Failure; Humans; Hydralazine; | 1983 |
Chronic afterload reduction in the treatment of congestive heart failure.
Topics: Captopril; Drug Evaluation; Heart Failure; Humans; Hydralazine; Prazosin; Proline; Quinazolines | 1983 |
Vasodilator therapy in children: acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation.
Topics: Adolescent; Captopril; Cardiac Catheterization; Child; Child, Preschool; Digoxin; Heart Failure; Hea | 1984 |
Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure.
Topics: Administration, Oral; Aged; Aldosterone; Chronic Disease; Epinephrine; Female; Heart Failure; Hemody | 1983 |
Vasodilators for chronic congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Vasodilator Agents | 1984 |
Chronic heart failure in the elderly: vasodilator therapy.
Topics: Aged; Blood Pressure; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine | 1983 |
Changes in plasma renin activity and haemodynamics during vasodilator therapy in conscious dogs with myocardial infarction or chronic volume overload.
Topics: Animals; Dogs; Heart Failure; Heart Rate; Hemodynamics; Hydralazine; Kinetics; Myocardial Infarction | 1983 |
Vasodilators in the treatment of congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Minoxidil; Nitroglycerin; Nitro | 1983 |
Vasodilator drugs.
Topics: Calcium Channel Blockers; Captopril; Heart Failure; Humans; Hydralazine; Minoxidil; Nitroglycerin; N | 1984 |
Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response.
Topics: Adult; Aged; Ambulatory Care; Cardiac Catheterization; Cardiomyopathy, Dilated; Chronic Disease; Dru | 1984 |
Nitrates in heart failure. Pathophysiological mechanisms and therapeutic applications.
Topics: Cardiac Output; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorb | 1984 |
Hemodynamic effects of hydralazine in infants with a large ventricular septal defect.
Topics: Blood Pressure; Cardiomegaly; Female; Heart Failure; Heart Septal Defects, Ventricular; Hemodynamics | 1982 |
[Hydralazine in chronic heart failure].
Topics: Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine | 1984 |
Improved cardiac performance during exercise following hydralazine treatment in chronic heart failure.
Topics: Aged; Chronic Disease; Digoxin; Diuretics; Exercise Test; Heart Failure; Hemodynamics; Humans; Hydra | 1984 |
Renal hemodynamic effects of vasodilation with nifedipine and hydralazine in patients with heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Glomerular Filtration Rate; Heart Failure; Humans; Hydr | 1984 |
Nitrates in acute myocardial infarction.
Topics: Blood Pressure; Cardiac Output; Drug Interactions; Furosemide; Heart Failure; Heart Rate; Humans; Hy | 1984 |
Hydralazine pharmacodynamics in the dog.
Topics: Animals; Blood Pressure; Disease Models, Animal; Dog Diseases; Dogs; Female; Heart Failure; Hemodyna | 1983 |
Pharmacokinetics of oral hydralazine in chronic heart failure.
Topics: Administration, Oral; Aged; Female; Heart Failure; Humans; Hydralazine; Hypertension; Kinetics; Male | 1983 |
Adjuvant therapy of chronic refractory cardiac failure with oral hydralazine and isosorbide dinitrate.
Topics: Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Digoxin; Diuretics; Drug Therapy, Co | 1983 |
Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects.
Topics: Blood Circulation; Blood Pressure; Endocardial Cushion Defects; Female; Heart Failure; Heart Rate; H | 1984 |
Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; M | 1984 |
Usefulness of vasodilator therapy in acute and chronic valvular regurgitation.
Topics: Aortic Valve; Aortic Valve Insufficiency; Combined Modality Therapy; Digoxin; Drug Therapy, Combinat | 1984 |
[The changes in plasma catecholamine and hemodynamics in the treatment of chronic congestive heart failure with hydralazine].
Topics: Adult; Aged; Catecholamines; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi | 1984 |
Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs.
Topics: Adult; Aged; Captopril; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitra | 1982 |
Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction.
Topics: Adult; Aged; Captopril; Heart Failure; Hemodynamics; Humans; Hydralazine; Physical Endurance; Prolin | 1982 |
The role of vasodilators in managing congestive heart failure.
Topics: Cardiotonic Agents; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Hydralazine; Myocardial | 1980 |
Pharmacodynamic basis of the use of vasodilators in the treatment of heart failure.
Topics: Cardiac Output; Diuretics; Heart Failure; Hemodynamics; Humans; Hydralazine; Myocardial Contraction; | 1980 |
Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.
Topics: Blood Pressure; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heart Rate; Hem | 1981 |
Postural hypotension and tachycardia during hydralazine--isosorbide dinitrate therapy for chronic heart failure.
Topics: Heart Failure; Hemodynamics; Humans; Hydralazine; Hypotension, Orthostatic; Isosorbide Dinitrate; Lo | 1981 |
Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs.
Topics: Administration, Oral; Aged; Captopril; Cardiac Catheterization; Drug Tolerance; Heart Failure; Hemod | 1981 |
Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance.
Topics: Acute Disease; Adult; Aged; Blood Pressure; Exercise Test; Heart Failure; Heart Rate; Hemodynamics; | 1981 |
The role of vasodilator therapy in the management of the patient with acute myocardial infarction.
Topics: Heart Failure; Heart Rupture; Hemodynamics; Humans; Hydralazine; Mitral Valve Insufficiency; Myocard | 1981 |
Sustained effect of hydralazine in long term treatment of CHF.
Topics: Aged; Blood Pressure; Cardiac Output; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydra | 1981 |
Vasodilator therapy in refractory congestive heart failure: a comparative analysis of hemodynamic and noninvasive studies.
Topics: Aged; Cardiac Output; Drug Evaluation; Echocardiography; Female; Heart Failure; Hemodynamics; Humans | 1982 |
Preload and afterload without anguish: a simplified framework.
Topics: Cardiac Output; Coronary Circulation; Heart Failure; Heart Function Tests; Humans; Hydralazine; Nitr | 1982 |
[Acute and chronic effects of dihydralazine in severe congestive heart failure at rest and during exercise (author's transl)].
Topics: Adult; Aged; Dihydralazine; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Long-Term Care | 1982 |
Dobutamine and hydralazine: comparative influences of positive inotropy and vasodilation on coronary blood flow and myocardial energetics in nonischemic congestive heart failure.
Topics: Adult; Catecholamines; Coronary Circulation; Dobutamine; Female; Heart Failure; Hemodynamics; Humans | 1983 |
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N | 1983 |
Effect of hydralazine on perfusion and metabolism in the leg during upright bicycle exercise in patients with heart failure.
Topics: Aged; Cardiac Output; Exercise Test; Female; Heart Failure; Humans; Hydralazine; Lactates; Lactic Ac | 1983 |
Hydralazine in chronic heart failure.
Topics: Heart Failure; Humans; Hydralazine | 1983 |
Determinants of circulatory response to intravenous hydralazine in congestive heart failure.
Topics: Female; Heart Failure; Heart Ventricles; Humans; Hydralazine; Male; Vascular Resistance | 1983 |
Use of hydralazine for intractable cardiac failure in childhood.
Topics: Antineoplastic Agents; Child; Chronic Disease; Female; Heart Failure; Humans; Hydralazine; Maxillary | 1980 |
Hydralazine in chronic CHF.
Topics: Administration, Oral; Aortic Valve Insufficiency; Cardiac Output; Chronic Disease; Drug Therapy, Com | 1981 |
Changes in control of renin release in congestive heart failure in dogs: response to acute and chronic vasodilator therapy.
Topics: Animals; Blood Pressure; Blood Volume; Dogs; Heart Failure; Heart Rate; Hydralazine; Myocardial Infa | 1982 |
Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.
Topics: Adult; Blood Pressure; Chronic Disease; Drug Tolerance; Female; Heart Failure; Heart Rate; Hemodynam | 1982 |
Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure.
Topics: Adult; Cardiac Output; Coronary Circulation; Female; Heart Failure; Humans; Hydralazine; Male; Middl | 1982 |
Vasodilators in heart failure secondary to coronary artery disease.
Topics: Cardiac Output; Coronary Disease; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Myocardi | 1982 |
Paradoxical response to the vasodilators.
Topics: Blood Pressure; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Male; Middle Aged; Mit | 1982 |
The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure.
Topics: Adult; Aged; Arterioles; Blood Pressure; Cardiac Output; Female; Heart Failure; Humans; Hydralazine; | 1982 |
Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment.
Topics: Aged; Cardiac Output; Female; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Oxygen; Pulmona | 1982 |
Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine.
Topics: Administration, Oral; Aged; Dipyridamole; Drug Evaluation; Female; Heart Failure; Hemodynamics; Huma | 1982 |
Tolerance to hydralazine in congestive heart failure.
Topics: Digoxin; Drug Tolerance; Heart Failure; Humans; Hydralazine | 1982 |
Clinical experience with hydralazine for treatment of otherwise intractable cough in dogs with apparent left-side heart failure.
Topics: Animals; Blood Pressure; Cough; Dog Diseases; Dogs; Female; Heart Failure; Heart Rate; Hydralazine; | 1982 |
Hydralazine and furosemide kinetics.
Topics: Adult; Creatinine; Drug Interactions; Female; Furosemide; Half-Life; Heart Failure; Humans; Hydralaz | 1982 |
Hemodynamic effects of vasodilator therapy in severe left heart failure combined with large atrial septal defects.
Topics: Blood Pressure; Heart Failure; Heart Septal Defects, Atrial; Hemodynamics; Humans; Hydralazine; Isos | 1982 |
Accuracy of cardiac output, oxygen uptake, and arteriovenous oxygen difference at rest, during exercise, and after vasodilator therapy in patients with severe, chronic heart failure.
Topics: Adult; Aged; Cardiac Output; Exercise Test; Female; Heart Failure; Humans; Hydralazine; Male; Middle | 1982 |
The longer term efficacy of vasodilators in heart failure.
Topics: Arteries; Heart Failure; Humans; Hydralazine; Nitrates; Vasodilator Agents; Veins | 1982 |
[Chronic Chagas' cardiopathy-- use of vasodilators in uncompensated heart failure].
Topics: Adolescent; Adult; Chagas Cardiomyopathy; Female; Ferricyanides; Heart Failure; Hemodynamics; Humans | 1982 |
[Hemodynamic effects of hydralazine at rest and during exercise, in patients with congestive heart failure (author's transl)].
Topics: Adult; Blood Pressure; Cardiac Output; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Mal | 1980 |
Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.
Topics: Adult; Aged; Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydral | 1981 |
Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure.
Topics: Aged; Blood Pressure; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Male; Mi | 1981 |
Prazosin and hydralazine in congestive heart failure. Regional hemodynamic effects in relation to dose.
Topics: Cardiac Output; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Humans; Hydra | 1981 |
Effect of furosemide in congestive heart failure.
Topics: Adult; Diuresis; Drug Therapy, Combination; Electrolytes; Female; Furosemide; Heart Failure; Humans; | 1981 |
Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.
Topics: Adult; Aged; Cardiac Output, Low; Drug Therapy, Combination; Exercise Test; Female; Heart Failure; H | 1981 |
Results of long-term vasodilator therapy in patients with refractory congestive heart failure.
Topics: Administration, Oral; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydralazine; I | 1981 |
Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure.
Topics: Chronic Disease; Digoxin; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Humans; Hydralazi | 1981 |
Acute and chronic effects of oral hydralazine on left ventricular pump function and renal hemodynamics in chronic left heart failure.
Topics: Administration, Oral; Adult; Aged; Female; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Hy | 1980 |
[Diuretic effects of furosemide in patients with congestive heart failure (author's transl)].
Topics: Adult; Aged; Diuresis; Female; Furosemide; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Ti | 1981 |
Effects of isosorbide dinitrate and hydralazine on regional metabolic responses to arm exercise in patients with heart failure.
Topics: Adult; Arm; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Lactates; Lactic Acid; | 1981 |
Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Coronary Circulation; Coronary Disease; Female; Heart F | 1981 |
[Limitations of long-term treatment with vasodilator agents in increasing maximum functional capacity in patients with left ventricular insufficiency].
Topics: Exercise Test; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Hydralazine; Male; Middle Aged | 1981 |
Hydrallazine alone in acute left ventricular failure.
Topics: Acute Disease; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Oxygen Inhalation Therapy | 1981 |
The effect of hydralazine on arrhythmias in congestive cardiomyopathy.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Cardiomyopathies; Female; Heart Failure; Heart Ra | 1981 |
Combined vasodilator therapy in the treatment of chronic heart failure.
Topics: Blood Pressure; Drug Therapy, Combination; Heart Failure; Heart Rate; Humans; Hydralazine; Isosorbid | 1981 |
Renal effects of nitroprusside and hydralazine in patients with congestive heart failure.
Topics: Adult; Aged; Ferricyanides; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Humans; Hydrala | 1980 |
Is there a drug of choice for vasodilator therapy in patients with refractory heart failure?
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Phentolamine; Prazosin; Vasodilator Agents | 1980 |
New therapies in the management of congestive heart failure.
Topics: Heart Failure; Humans; Hydralazine; Prazosin; Quinazolines | 1980 |
New approaches to therapy of acute heart failure.
Topics: Antihypertensive Agents; Dobutamine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroprusside; Ox | 1980 |
Effects of vasodilators on pulmonary hemodynamics and gas exchange in left ventricular failure.
Topics: Adult; Aged; Blood Gas Analysis; Blood Pressure; Ferricyanides; Heart Failure; Heart Rate; Hemodynam | 1980 |
Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators.
Topics: Adult; Aged; Cardiac Output; Energy Metabolism; Heart Failure; Hemodynamics; Humans; Hydralazine; La | 1980 |
Dose requirements of hydralazine in patients with severe chronic congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Female; Heart Failur | 1980 |
Hemodynamic evaluation of hydralazine dosage in refractory heart failure.
Topics: Aged; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Ma | 1980 |
Beneficial effects of afterload reduction therapy in patients with congestive heart failure and moderate aortic stenosis.
Topics: Adult; Aged; Aortic Valve Stenosis; Blood Pressure; Cardiac Output; Female; Heart Failure; Heart Rat | 1980 |
Vasodilator therapy of chronic congestive heart failure.
Topics: Ambulatory Care; Chronic Disease; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Quinazolin | 1980 |
Hydralazine in chronic left heart failure.
Topics: Cardiac Output; Heart Failure; Humans; Hydralazine; Stroke Volume | 1980 |
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Volume; Chronic Disease; Echocardiography | 1980 |
Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Female; Heart Failure; Heart Rate | 1980 |
Hemodynamic effects of nifedipine in congestive heart failure.
Topics: Adult; Cardiac Output; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Male; M | 1980 |
Effect of vasodilator drugs on exercise performance in cardiac failure. Comparison of hydralazine and prazosin.
Topics: Adult; Aged; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; Middle Aged; Oxygen Con | 1980 |
Haemodynamic effects of hydralazine at rest and during exercise in patients with chronic heart failure.
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi | 1980 |
Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure.
Topics: Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Humans; Hydralazine; Myocardial Contrac | 1980 |
Noninvasive assessment of left ventricular effects of hydralazine in heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Heart; Heart Failure; Heart Rate; Heart Ventricles; Hum | 1980 |
Systolic time intervals. Noninvasive assessment of vasodilator therapy for congestive failure.
Topics: Adult; Digoxin; Echocardiography; Electrocardiography; Furosemide; Heart Failure; Humans; Hydralazin | 1981 |
[Treatment of cardiac insufficiency with systemic vasodilator agents].
Topics: Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrites; Nitroprusside; Prazosin; Vasodilator Age | 1980 |
Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Cardiotonic Agents; Drug Ther | 1981 |
Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin.
Topics: Animals; Dogs; Enalaprilat; Heart Failure; Hydralazine; Mesenteric Veins; Nitroglycerin; Plethysmogr | 1995 |
Impact of left ventricular cavity size on survival in advanced heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Body Constitution; Cause of Death; Cohort Studies; Death, | 1993 |
Control of arginine vasopressin and congestive heart failure.
Topics: Arginine Vasopressin; Heart Failure; Humans; Hydralazine | 1993 |
Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.
Topics: Animals; Aorta; Drug Therapy, Combination; Gene Expression Regulation, Enzymologic; Heart Failure; H | 1996 |
Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Dog Dis | 1996 |
Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Cardiac Out | 1997 |
The AHCPR clinical practice guideline for heart failure revisited.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Calcium Chann | 1997 |
Effects of hydralazine on renal sympathetic nerve activity in normal and congestive heart failure rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Coronary Vessels; Heart Failure; Hear | 1997 |
Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dogs; Enalaprilat; Female; Heart Failure; Hemod | 1998 |
Does gender bias exist in the medical management of heart failure?
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiolo | 2000 |
Tailored treatments.
Topics: Black or African American; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Hydralaz | 2001 |
Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Collagen; Heart Failure; Heart Ventri | 2001 |
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Dogs; Electr | 2001 |
Treatment of congestive heart failure.
Topics: Angioedema; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hydrala | 2002 |
Treatments for heart-failure: stimulation or unloading ?
Topics: Heart Failure; Humans; Hydralazine; Myocardial Contraction; Nitrates; Phentolamine; Stimulation, Che | 1979 |
Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Heart Ventricles; Hemodynamics; Humans; H | 1978 |
Haemodynamic effects of hydrallazine and of hydrallazine plus glyceryl trinitrate paste in heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Heart Failure; Humans; Hydra | 1978 |
Afterload reduction in the treatment of cardiac failure.
Topics: Blood Pressure; Heart Failure; Humans; Hydralazine; Nitroglycerin; Nitroprusside; Phentolamine; Praz | 1978 |
[Vasodilator therapy of heart failure].
Topics: Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Prazosin; Stroke Volume; | 1979 |
[Treatment of severe chronic cardiac insufficiency with dihydralazine. Short-and median-term results].
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Dihydralazine; Drug Evaluation; Female; Heart Fa | 1979 |
[Hemodynamic effects of hydralazine in the cardiac insufficiency of non-obstructive myocardiopathy].
Topics: Adult; Cardiomyopathies; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; Middle Aged | 1979 |
[Treatement of circulatory insufficiency with vasodilator agents].
Topics: Blood Circulation; Ferricyanides; Heart Failure; Humans; Hydralazine; Nitroglycerin; Nitroprusside; | 1979 |
Non-parenteral combined afterload and preload reduction therapy in congestive heart failure.
Topics: Adult; Aged; Cardiac Output; Drug Combinations; Follow-Up Studies; Heart Failure; Hemodynamics; Huma | 1978 |
Nonparenteral vasodilator therapy for chronic congestive heart failure.
Topics: Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglycerin; Prazosin; Vasodilator Age | 1979 |
[Hemodynamic effects of oral dihydralazine and sublingual isosorbide dinitrate, alone and in combination in chronic heart failure].
Topics: Administration, Oral; Aged; Chronic Disease; Dihydralazine; Drug Therapy, Combination; Female; Heart | 1979 |
Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Female | 1977 |
Afterload reduction in congestive heart failure.
Topics: Dopamine; Heart Failure; Humans; Hydralazine; Nitrates; Nitroglycerin; Nitroprusside; Phentolamine; | 1978 |
Precipitation of heart failure following sudden withdrawal of hydralazine.
Topics: Administration, Oral; Aged; Aortic Valve Insufficiency; Digoxin; Furosemide; Heart Failure; Hemodyna | 1979 |
Hydralazine in the management of left ventricular failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Female; Heart Failure; Hemodynami | 1979 |
Influence of vasodilators used in the therapy of heart failure on platelet aggregation.
Topics: Dihydralazine; Heart Failure; Humans; Hydralazine; In Vitro Techniques; Phentolamine; Platelet Aggre | 1979 |
Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure.
Topics: Administration, Oral; Aged; Cardiac Output; Drug Evaluation; Drug Therapy, Combination; Heart Failur | 1979 |
Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
Topics: Chronic Disease; Dobutamine; Dopamine; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; Moni | 1979 |
Chronic oral vasodilator therapy to control heart failure in postinfarction ventricular septal defect.
Topics: Administration, Oral; Aged; Drug Therapy, Combination; Female; Heart Failure; Heart Rupture; Heart S | 1979 |
Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
Topics: Adult; Aged; Cardiac Output; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi | 1979 |
Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.
Topics: Adult; Aged; Chronic Disease; Ferricyanides; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; | 1979 |
[Treatment of advanced heart failure with hydralazine and isosorbide dinitrate (author's transl)].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Female; Heart Failure; Human | 1979 |
Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside.
Topics: Administration, Oral; Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Heart Failure | 1978 |
Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy.
Topics: Aged; Coronary Disease; Digitalis Glycosides; Female; Furosemide; Heart Failure; Humans; Hydralazine | 1978 |
Outflow resistance as a regulator of left ventricular performance.
Topics: Blood Pressure; Cardiac Output; Heart Failure; Heart Rate; Heart Ventricles; Hemodynamics; Humans; H | 1978 |
Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure.
Topics: Blood Pressure; Cardiac Output; Delayed-Action Preparations; Heart Failure; Heart Rate; Heart Ventri | 1978 |
Vasodilator and inotropic therapy of heart failure [panel discussion].
Topics: Animals; Cardiac Output; Coronary Circulation; Dobutamine; Dogs; Dose-Response Relationship, Drug; H | 1978 |
Use of vasodilator drugs in congestive heart failure.
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitroprusside; Prazosin; Vasodilator Agent | 1978 |
Combination vasodilator therapy for severe chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosor | 1976 |
Oral hydralazine therapy for chronic refractory heart failure.
Topics: Adult; Aged; Blood Pressure; Capillaries; Chronic Disease; Female; Heart Failure; Heart Rate; Hemody | 1976 |
Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Ferricyanides; Heart Failure; Hea | 1977 |
Recent developments in the pharmacotherapy of cardiac failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Digoxi | 1992 |
Vasodilator therapy and survival in chronic congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Prospective Studies; Randomized Controlled Trials as | 1992 |
Baroreceptor-mediated release of vasopressin in patients with chronic congestive heart failure and defective sympathetic responsiveness.
Topics: Adult; Aged; Cardiac Catheterization; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; | 1992 |
Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure.
Topics: Animals; Diastole; Drug Therapy, Combination; Drug Tolerance; Heart Failure; Hydralazine; Nitroglyce | 1991 |
Usefulness of hydralazine to withdraw from dobutamine in severe congestive heart failure.
Topics: Adult; Dobutamine; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male | 1991 |
Does the magnitude of mitral regurgitation determine hemodynamic response to vasodilation in chronic congestive heart failure?
Topics: Adult; Aged; Chronic Disease; Heart Failure; Heart Valve Prosthesis; Hemodynamics; Humans; Hydralazi | 1991 |
Acute reduction of atrial overload during vasodilator and diuretic therapy in advanced congestive heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Captopril; Diuretics; Drug Therapy, Combination; Female; | 1990 |
Impact of a drug-use review program intervention on prescribing after publication of a randomized clinical trial.
Topics: Attitude of Health Personnel; Drug Prescriptions; Drug Utilization; Heart Failure; Hospitals, Vetera | 1990 |
Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?
Topics: Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Time Fact | 1987 |
Digitalis for patients with heart failure.
Topics: Digitalis; Digoxin; Heart Failure; Humans; Hydralazine; Plants, Medicinal; Plants, Toxic | 1989 |
Effects of vasodilators on the coronary circulation in congestive heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Cardiomegaly; Cilazapri | 1988 |
Humoral adaptation mechanisms and clinical outcome during vasodilator therapy.
Topics: Atrial Natriuretic Factor; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Mal | 1988 |
Current indications for vasodilator therapy for left ventricular failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Hemodynamics; Hu | 1985 |
Guidelines for vasodilator therapy of congestive heart failure in infants and children.
Topics: Captopril; Child; Child, Preschool; Enalapril; Heart Diseases; Heart Failure; Heart Ventricles; Hemo | 1987 |
Treatment of cardiac failure in infants.
Topics: Alprostadil; Captopril; Digitalis Glycosides; Diuretics; Drug Therapy, Combination; Heart Failure; H | 1986 |
[Long-term vasodilator therapy of chronic refractory heart failure in patients with dilated cardiomyopathy].
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chronic Disease; Drug Therapy, Combination; Echocardiography; | 1986 |
Role of nitrates in congestive heart failure.
Topics: Dosage Forms; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbid | 1987 |
[The effect of apressin on the results of the Valsalva test in ischemic heart disease].
Topics: Aged; Coronary Disease; Female; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Valsalva Mane | 1988 |
[Systolic intervals in dilated heart insufficiency. Influence of vasodilator treatment].
Topics: Aged; Captopril; Female; Heart Failure; Heart Ventricles; Humans; Hydralazine; Isosorbide Dinitrate; | 1988 |
[Current management of left heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Catecholamines; Digitalis Glycoside | 1987 |
Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure.
Topics: Aged; Blood Pressure; Captopril; Drug Therapy, Combination; Epinephrine; Female; Heart Failure; Hear | 1986 |
Vasodilators as first-line therapy for congestive heart failure: a comparative hemodynamic study of hydralazine, digoxin, and their combination.
Topics: Aged; Digoxin; Drug Combinations; Exercise Test; Heart Failure; Hemodynamics; Humans; Hydralazine; I | 1987 |
Severe hypertension, propranolol, and acute pulmonary edema.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Hypertension | 1987 |
[Effects of hydralazine therapy in patients with chronic congestive heart failure].
Topics: Adult; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; Middle Aged; | 1987 |
[Effect of peripheral vasodilators on thrombocyte aggregation in chronic circulatory insufficiency].
Topics: Adult; Aged; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; | 1986 |
Comparative efficacy of digoxin, hydralazine and combination therapy in chronic congestive heart failure.
Topics: Adult; Chronic Disease; Digoxin; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazi | 1986 |
Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure.
Topics: Angiography; Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Echocardiography; Female; Heart | 1987 |
Static exercise with congestive heart failure and the response to vasodilating drugs.
Topics: Adolescent; Adult; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; Middle Aged; Phys | 1987 |
[Long-term effects of digoxin and hydralazine in patients with chronic cardiac insufficiency].
Topics: Adult; Aged; Chronic Disease; Digoxin; Drug Administration Schedule; Drug Therapy, Combination; Fema | 1985 |
Mixed venous blood temperature response to exercise in heart failure patients treated with short-term vasodilators.
Topics: Adult; Aged; Body Temperature; Captopril; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; | 1985 |
Treatment of congestive heart failure by altering loading conditions of the heart.
Topics: Captopril; Cardiac Output; Child; Digoxin; Dopamine; Drug Therapy, Combination; Heart; Heart Failure | 1985 |
Vasodilator therapy for chronic congestive heart failure.
Topics: Captopril; Cardiac Catheterization; Heart Failure; Hospitalization; Humans; Hydralazine; Myocardial | 1985 |
[Peripheral vasodilator in cardiac insufficiency in the acute period of myocardial infarction].
Topics: Cardiomyopathy, Dilated; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine | 1985 |
[Combined use of isoprenaline and hydralazine in the treatment of chronic circulatory insufficiency].
Topics: Adult; Cardiomyopathy, Dilated; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; H | 1985 |
Hydralazine in the management of chronic congestive heart failure.
Topics: Heart Failure; Hemodynamics; Humans; Hydralazine | 1985 |
[Role of dihydralazine in the treatment of chronic cardiac insufficiency].
Topics: Aged; Arterioles; Cardiac Output; Chronic Disease; Dihydralazine; Follow-Up Studies; Heart Failure; | 1985 |
Acute hemodynamic effects of hydralazine in dogs with chronic mitral regurgitation.
Topics: Animals; Blood Pressure; Cardiac Output; Dog Diseases; Dogs; Heart Failure; Hemodynamics; Hydralazin | 1985 |
Effects of hydralazine on pressure-volume and stress-volume relations in congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; Middl | 1985 |
Determinants of systemic availability of oral hydralazine in heart failure.
Topics: Aged; Biological Availability; Heart Failure; Hemodynamics; Humans; Hydralazine; Kinetics; Liver Cir | 1985 |
[Dihydralazine treatment of cardiac insufficiency in children].
Topics: Dihydralazine; Heart Failure; Humans; Hydralazine; Infant | 1985 |
[Dihydralazine treatment of cardiac insufficiency in children].
Topics: Adolescent; Child; Child, Preschool; Dihydralazine; Drug Evaluation; Female; Heart Failure; Humans; | 1985 |
[Effect of hydralazine on systemic hemodynamics in patients with cardiac insufficiency].
Topics: Adult; Aged; Blood Circulation; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; Midd | 1985 |
[Effect of hydralazine on pressure in the pulmonary artery and on blood redistribution in the vessels].
Topics: Blood Pressure; Blood Volume; Drug Evaluation; Heart Failure; Humans; Hydralazine; Pulmonary Artery; | 1985 |
[A case of development of cardiac rhythm migration after intake of hydralazine].
Topics: Arrhythmia, Sinus; Heart Failure; Humans; Hydralazine; Male; Middle Aged | 1985 |
[Therapy of arterial hypertension. Results, possibilities, methods].
Topics: Adrenergic beta-Antagonists; Cerebrovascular Circulation; Coronary Disease; Diet; Diuretics; Electri | 1970 |
[Indications of antihypertensive treatment in non-malignant hypertension].
Topics: Antihypertensive Agents; Aortic Aneurysm; Benzothiadiazines; Cerebrovascular Disorders; Coronary Dis | 1974 |
Aggressive drug therapy in accelerated hypertension.
Topics: Antihypertensive Agents; Aortic Aneurysm; Brain Diseases; Cerebrovascular Disorders; Diazoxide; Ferr | 1974 |
Hypertension: challenge in preventive medicine.
Topics: Aged; Aneurysm; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therap | 1973 |
[What is reliable in the therapy of hypertension?].
Topics: Arteriosclerosis; Cerebral Hemorrhage; Diet, Reducing; Diet, Sodium-Restricted; Guanethidine; Health | 1970 |
An approach to the medical treatment of hypertension in the aged.
Topics: Age Factors; Aged; Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Diuretics; | 1969 |